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ABSTRACT 
 
Growth promoting technologies such as beta agonists and hormone implants are 
used extensively throughout the feedlot industry (Samuelson et al., 2016). These 
technologies are known to improve performance and efficiency of growth and thus are 
vital to sustained profitability for cattle producers. The ability to further improve the 
effectiveness of these technologies would improve productivity of cattle and may be 
accomplished through the strategic supplementation of trace minerals such as Cu. 
Although industry recommendations for Cu are two times NASEM (2016) 
recommendations, little research has evaluated trace mineral supplementation in addition 
to growth promoting technologies. Therefore, the effects of greater concentrations of 
minerals such as Cu in the diet of cattle utilizing growth promoting technologies has not 
yet been validated. The research trials described in this thesis were designed to 1) 
determine the effect of Cu status of finishing beef steers on beta agonist induced growth 
performance and 2) examine the impacts of industry rates of Cu supplementation on the 
implant growth response of finishing feedlot steers. Through our first research objective, 
the supplementation of varying concentrations of Cu to finishing feedlot cattle 
differentially impacted the beta agonist induced performance response of cattle. Within 
cattle receiving the beta agonist treatment, performance was greatest at Cu 
supplementation at NASEM (2016) recommendations. These performance differences 
were observed in Cu supplemented cattle with adequate liver Cu status suggesting further 
classification of Cu status for optimal growth is needed. Through our second study 
performance was impacted by an interaction between implant and Cu in which cattle not 
ix 
 
 
supplemented with Cu experienced a 24.7% increase in ADG due to implant while 
industry recommendations of Cu supplementation resulted in a 15.3% improvement in 
ADG due to implant. Additionally, liver Cu concentrations tended to increase and liver 
Mn concentrations decreased 14 days after implantation, while liver Zn and plasma Zn 
revealed trends for decreases due to implant. Together these studies indicate Cu may 
impact the physiological response to growth promoting technologies and that implants 
may alter mineral metabolism. Additionally, these data revealed that supplementation of 
Cu beyond NASEM (2016) recommendations may not promote optimal performance 
from cattle utilizing growth promoting technologies. Collectively, the studies presented in 
this thesis find that concentrations of Cu commonly supplemented within the industry are 
not merited. This work warrants additional research to better understand the role of Cu in 
growth induced through technologies such as beta agonists and hormone implants.  
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CHAPTER 1. GENERAL INTRODUCTION 
Growth promoting technologies within the feedlot have substantially improved 
the productivity of the beef industry. Both hormonal implants and beta agonists (BA) are 
common technologies used in the industry today. Hormonal implants have been utilized 
for more than 50 years and nearly 70 and 85 percent of cattle represented in a survey of 
consulting nutritionists are implanted with a two implant protocol or fed a BA, 
respectively (Samuelson et al., 2016). Such practices indicate the importance of growth 
promoting technologies to maximize production and efficiencies throughout all stages of 
production in the feedlot sector.  
Enhanced growth seen in cattle receiving hormonal implants and BA may lead to 
increased nutritional requirements such as minerals. Particularly, copper (Cu) may be 
required in this state of increased growth due to its support of extracellular matrix 
formation through the Cu dependent enzyme lysyl oxidase (LOX) that forms crosslinking 
of collagen and elastin supporting the structural integrity of the cell (Rucker et al., 1998). 
Further, implanted steers have been observed to have lesser liver Cu status 14 days after 
reimplantation (20 mg E2 and 200 mg TBA) than nonimplanted counterparts suggesting 
Cu may be important in hormonal implant induced growth (Niedermayer et al., 2018). 
Additionally, Cu appears to have a potential role in the BA pathway through its inhibition 
of phosphodiesterase (PDE) in cultured adipocytes (Krishnamoorthy et al., 2016).  
Therefore, a combination of strategic trace mineral supplementation in addition to 
growth promoting technologies may be required to optimize beef production. In two 
studies, this research examines the impacts of varying concentrations of dietary Cu 
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provided to beef finishing steers either receiving the BA ractopamine hydrochloride or 
with or without a potent steroid hormone implant.     
Thesis Organization 
The following chapter, Chapter II, will present a detailed review of the literature 
regarding the mechanisms of BA and hormonal implants in addition to the importance of 
the biological processes of Cu in growing cattle. The following two chapters, chapters III 
and IV, will present research that is intended to be published in the Journal of Animal 
Science or the Professional Animal Scientist. The research presented in chapter III will 
focus on the effect of initial liver copper status in finishing steers fed three dietary 
concentrations of copper with or without ractopamine hydrochloride on liver copper 
status, growth performance, and carcass characteristics. Chapter IV will concentrate on 
the effect of supplementation of copper to steers that either received a potent combination 
implant or did not receive an implant on performance and carcass characteristics. This 
thesis will then conclude in Chapter V with overall research findings and proposals for 
further research. 
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CHAPTER 2. LITERATURE REVIEW 
Beta Agonists 
The use of BA in the cattle industry is prominent due to the desirable growth 
efficiencies observed with use in feedlot cattle. Nearly 85% of cattle represented in 
surveys of either consulting nutritionists or feedlot managers are fed a BA (Birch, 2015; 
Samuelson et al., 2016). A meta-analysis of cattle fed either zilpaterol hydrochloride 
(ZH; tradename Zilmax) or ractopamine hydrochloride (RAC; tradename Optaflexx or 
Actogain45) indicated that the use of BA improved live BW 8 kg and ADG by 0.15 to 
0.19 kg/day for both ZH and RAC (Lean et al., 2014). Further analysis revealed that 
HCW was 15 kg heavier for cattle fed ZH with RAC fed cattle having improved HCW 
over control animals but to a lesser degree than ZH (Lean et al., 2014). This improvement 
in growth is animal dependent, as animals are born with a finite number of muscle fibers 
indicating that growth elicited from BA use is a result of hypertrophy as fiber DNA 
content does not increase (Mills, 2002; Johnson et al., 2014). Growth is elicited through 
the beta-adrenergic receptor (β-AR) belonging to a family of G-protein coupled receptors 
(GPCR; Johnson et al., 2014).  
There are three known β-AR, including β1AR, β2AR, and  β3AR that are found in 
different proportions throughout body tissues (Johnson et al., 2014). In cattle, skeletal 
muscle contains over 99% β2 receptors while adipose tissue contains greater than 90% β2 
receptors (Johnson et al., 2014). The importance of receptor type is due to the affinity of 
BA to these specific receptors. Currently the only BA available in the U.S., RAC is a β1 
agonist with partial β2 agonist activity (Johnson et al., 2014). In contrast, ZH, while 
having an affinity for both β1 and β2 receptors, is predominantly a β2 agonist (Verhoeckx 
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et al., 2005).  In addition to receptor types, there are differences in the types of BA. Some 
BA are full agonists that allow maximum stimulation after binding to the β-AR while 
others are classified as partial agonists for their incomplete activity (Rosenbaum et al., 
2009; Warne et al., 2011; Manglik et al., 2015). Furthermore, a third type of ligand called 
an antagonist can bind to the β-AR but does not elicit a response, therefore blocking the 
receptor site from an active agonist (Rosenbaum et al., 2009; Warne et al., 2011; Manglik 
et al., 2015). The biological importance of these agonists and antagonists are 
demonstrated in the BA pathway. 
Beta agonist pathway 
 Beta agonists do not directly act upon muscle fibers to elicit growth, but instead 
trigger a cascade of effects by binding to β-AR on the plasma membrane of most 
mammalian cells (Mersmann, 1998). These GPCR are composed of seven hydrophobic 
transmembrane domains with hydrophilic segments in between these domains alternating 
intracellularly and extracellularly (Strader et al., 1989; Mersmann, 1998; Rosenbaum et al., 
2009). These domains are continuous structures with each hydrophobic region containing 
20 to 25 amino acids with variable lengths of hydrophilic regions between each domain 
spanning in total over 400 amino acids in length  (Strader et al., 1989; Mersmann, 2002). 
The two ends of the membrane protein amino acid chain are on inverse sides of the plasma 
membrane. The amino-terminus is located on the extracellular portion while the carboxy-
terminus is situated intracellularly (Strader et al., 1989; Strosberg and Pietri-Reuxel, 1996). 
The extracellular segments of these domains play a critical role in the binding site of the 
BA as amino acids from several of the transmembrane loops interact with the ligand as it 
binds to the receptor (Mersmann, 1998). The seven extracellular domains are arranged in 
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a circular formation with extracellular portions of transmembrane domains 3, 4, 5, 6, and 
7 forming the main ligand binding pocket, while transmembrane domains 1, 2, 3, and 7 
form the shallow minor binding pocket on the extracellular side of the GPCR (Schwartz et 
al., 2006).  
Examination of the full agonists carmoterol and isoprenaline alongside the partial 
agonists salbutamol and dobutamine show that these four agonists bind to the ligand-
binding pocket of the β-AR in a similar fashion. A secondary amine and β-hydroxyl group 
form potential hydrogen bonds with aspartic acid 121 and asparagine 329 residues except 
for in dobutamine which lacks the β-hydroxyl group (Warne et al., 2011). Another 
hydrogen bond is also formed with the asparagine 310 residue of the β-AR (Warne et al., 
2011). In addition, all agonists form hydrogen bonds with serine 211 and induce a 
conformational change in serine 212 to allow for a hydrogen bond to form with asparagine 
310 (Warne et al., 2011). When full agonists are bound to the β-AR, conformation changes 
in the side chains of serine 212 and serine 215 weaken the interactions between 
transmembrane domains 4 and 5 while strengthening the interaction between 
transmembrane 5 and 6 with an added hydrogen bond (Warne et al., 2011). Both the 
weakening and strengthening of these bonds may facilitate the movement of 
transmembrane 5 and 6 as has been noted during rhodopsin activation (Park et al., 2008; 
Warne et al., 2011). This movement of transmembrane domains is thought to be due to 
allosteric coupling of the ligand binding pocket and the cytoplasmic domain of the β-AR 
(Manglik et al., 2015). In addition to the binding of the agonist to the ligand binding pocket, 
the G-protein, Gs  is required for the β-AR to elicit a response to the agonist subsequently 
resulting in the outward movement of transmembrane 6 (Manglik et al., 2015). Further, the 
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binding of Gs to β-AR stabilizes the cytoplasmic region of transmembrane 7 and elicits a 
change in the structure of the extracellular loop between transmembrane 4 and 5 (Devree 
et al., 2016). A β2-AR-Gs complex has been shown to have two aromatic residues, 
phenylalanine 193 and tyrosine 308, that move approximately 2-2.5 Å closer to each other 
to form a lid-like structure over the β-AR ligand binding site (Devree et al., 2016). This lid 
provides protection to the binding site from other potential ligands as well as from the 
dissociation of a bound ligand (Devree et al., 2016). Movement of the β-AR 
transmembrane domains may be enhanced by the methylation of phospholipids in the 
plasma membrane (Hirata et al., 1979). The stimulation of rat reticulocytes with L-
isoproterenol resulted in increased phospholipid methylation and thus fluidity of the 
membrane while also increasing the activation of adenylyl cyclase from the β-AR activity 
(Hirata et al., 1979). This increased fluidity of the plasma membrane is believed to enhance 
the β-AR coupling to adenylyl cyclase by allowing the domains to move more easily 
through the membrane to obtain their active form (Hirata et al., 1979).  
 The G proteins necessary to couple agonist activation of β-AR to adenylyl cyclase 
activity  are guanine nucleotide binding regulatory proteins (Gilman, 1984). Two G 
proteins have a role in this response. The Gs protein is a stimulating protein while Gi 
inhibits the coupling of β-AR to adenylyl cyclase for activation (Rasenick et al., 1994; 
Rosenbaum et al., 2009). Both of these proteins are heterotrimeric with α, β, and γ subunits 
that are all required for activation (Rasenick et al., 1994). Following the agonist binding to 
the β-AR a G protein is bound intracellularly catalyzing a reaction leading to the release of 
GDP from the α subunit of the G protein (Devree et al., 2016). Intracellular GTP then binds 
the G protein rendering it in the active state (Strader et al., 1989; Sprang, 1997). The Gs 
7 
 
subunit dissociates from the Gβγ subunit and is responsible for the activation of adenylyl 
cyclase to generate cAMP (Tang and Gilman, 1992). The production of cAMP can have 
various biological effects as it is a secondary intracellular messenger (Robison et al., 1968). 
Within the BA pathway, cAMP activates protein kinase A (PKA; Beavo et al., 1974). The 
structure of PKA is composed of two catalytic subunits as well as 2 regulatory subunits; 
cAMP binds directly to the regulatory subunits allowing for the release of the active 
catalytic subunits (Zhang et al., 2012). The catalytic subunits of PKA are responsible for 
the phosphorylation of specific target proteins such as hormone sensitive lipase in the BA 
pathway (Mersmann, 1998; Zhang et al., 2012). The use of hormone sensitive lipase knock 
out mice given the universal BA isoproterenol demonstrated that activation of hormone 
sensitive lipase is responsible for the lipolysis response from BA use as knock out mice 
had lesser circulating concentrations of free fatty acids (Haemmerle et al., 2002).  
Beyond the stimulation of lipolysis, BA positively impact muscle accretion in part 
by decreasing protein degradation (Mersmann, 1998). The supplementation of clenbuterol 
to healthy rats increased muscle weight while also increasing the rate in which protein and 
RNA accumulated in the muscles (Reeds and Hay, 1986). Further, the treatment of 
bupivacaine hydrochloride injured muscle cells with the BA fenoterol resulted in greater 
restoration of muscle than saline treated rats signifying that BA promote regenerative 
muscle growth as well as new muscle accretion in healthy tissue (Beitzel et al., 2004). In 
addition to muscle tissue repair, cAMP dependent muscle hypertrophy was observed in 
muscle Gsα knock out mice as muscle mass of these mice was less than wild type mice 
indicating that Gsα activation of muscle hypertrophy is necessary (Chen et al., 2009).  
Further, the BA clenbuterol was observed to produce a dose dependent decline in muscle 
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proteolysis of treated rats (Navegantes et al., 2000). Testing the effects of clenbuterol on 
proteolysis, cAMP inhibitors DBcAMP and IBMX were each incubated with the BA 
(Navegantes et al., 2000). The addition of inhibitors to clenbuterol resulted in no difference 
in proteolysis activity between treatment, although values were still lesser than in control 
rats (Navegantes et al., 2000). This suggests that the proteolytic effects of BA are mediated 
through cAMP which likely activates a protein kinase that phosphorylates and thus 
inactivates the mechanism for muscle proteolysis (Navegantes et al., 2000). Presumably, 
this mechanism is the cAMP facilitated production of calpastatin that leads to decreased 
muscle proteolysis through the inhibition of calpain (Cong et al., 1998).  
Further work has indicated that BA muscle accretion response is not only due to 
activation of the cAMP pathway. The Akt/mTOR pathway has been proposed to be 
stimulated by the BA clenbuterol with the β and γ subunits of the Gs protein mediating this 
activation (Sneddon et al., 2001; Kline et al., 2007). Supplementation of clenbuterol to rats 
resulted in an increase in p70 S6 kinase and 4E-BP1, the downstream metabolites of the 
Akt/mTOR pathway that result in protein synthesis (Sneddon et al., 2001; Kline et al., 
2007). Further treating rats with the mTOR inhibitor rapamycin resulted in a lessening of 
the clenbuterol protein accretion effect (Kline et al., 2007). Although it is known that BA 
promote protein accretion, the specific mechanism by which stimulated G proteins activate 
this hypertrophy is not fully understood.  Although increased muscle accretion due to BA 
is readily accepted, additional studies are warranted to fully understand how both the 
Akt/mTOR and cAMP pathway mediate BA-induced growth.  
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Beta agonist regulation 
 Following the activation of β-AR, the receptor must be regulated to manage the 
signal. Only three families of proteins are known to interact directly with agonist 
activated GPCRs including G-protein-coupled-receptor-kinases (GRK), β-arrestins, and 
G-proteins (Lefkowitz and Shenoy, 2005). The β-adrenergic receptor kinase (βARK) is 
considered part of the GRK family. Through the stimulation of purified hamster lung β-
AR with isoproterenol, βARK was determined to phosphorylate agonist occupied β-AR 
as receptor phosphorylation increased up to 10-fold with stimulation in comparison to the 
antagonist bound β-AR (Benovic et al., 1986). This phosphorylation is the beginning of 
the regulation process. The βARK is initiated once the β-AR is bound by an agonist, after 
which βARK is translocated from the cytosol to the plasma membrane to phosphorylate 
the β-AR (Strasser et al., 1986). Serine and threonine residues on either the carboxy-
terminal tail region or the third cytoplasmic loop of β-AR are the target sites of 
phosphorylation for GRK (Reiter and Lefkowitz, 2006; Ma and Pei, 2007). Both β1-AR 
and β2-AR cytoplasmic tails contain 10-11 serine and threonine for such phosphorylation 
(Hausdorff et al., 1990). In addition to βARK, PKA, a downstream product of GPCR 
activation, can phosphorylate the β-AR and uncouple the G-protein (Baillie et al., 2003). 
Both PKA and βARK are required to work in concert to cause desensitization of β-AR, 
but may work individually under long term exposure to BA (Hausdorff et al., 1990). In 
the case of mutated β2-AR from Chinese hamster fibroblasts either lacking the βARK or 
PKA phosphorylation site stimulation with 10 nM of isoproterenol revealed insight into 
β-AR  phosphorylation (Hausdorff et al., 1989). Cells lacking the βARK sites 
experienced 80% more phosphorylation over basal rates (Hausdorff et al., 1989). In 
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contrast, receptors lacking either PKA or both PKA and βARK phosphorylation sites 
only experienced 30-40% phosphorylation over basal levels (Hausdorff et al., 1989). 
These data suggest that at low isoproterenol stimulation phosphorylation is preferred at 
the carboxyl-terminal βARK sites.  
Following phosphorylation, β-arrestins are recruited to the agonist bound β-AR 
with high affinity as an essential cofactor to βARK (Hausdorff et al., 1990; Reiter and 
Lefkowitz, 2006; Deshpande et al., 2008). Both the agonist induced receptor 
conformation alteration and the phosphorylation of the β-AR lead to the recruitment of β-
arrestins to the β-AR (Gurevich and Benovics, 1993; Lefkowitz, 1998). It is suggested 
that β-arrestin engages with the β-AR through a two-step mechanism that first involves 
the interaction between the phosphorylated carboxy-terminal tail of the receptor and the 
amino-terminal domain of the β-arrestin followed by the insertion of the finger loop 
within the core of the β-AR (Shukla et al., 2014). Through chemical cross-linking and 
modeling, this core interaction is thought to be between the lysine 235 residue on the 
third intracellular loop of the β-AR, specifically in β2V2R and the lysine 77 residue in the 
finger loop of β-arrestin1 (Kumari et al., 2016). Further, superimposing the structures of 
β-AR bound β-arrestin and β-AR bound Gsα suggests steric hindrance by β-arrestin due to 
the overlapping presence of both β-arrestin and Gsα (Kumari et al., 2016). This steric 
hindrance blocks the interaction of G-proteins with the β-AR, therefore uncoupling the 
G-protein from the β-AR and discontinuing the BA activated GPCR cascade of effects 
(Deshpande et al., 2008; Shenoy and Lefkowitz, 2011). This uncoupling of the G-protein 
leads to the desensitization of the β-AR (Shenoy et al., 2001). The effectiveness of β-
arrestin regulation of GPCR activity can be demonstrated through β-arrestin2 knock out 
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airway smooth muscle cells derived from mice that were stimulated with isoproterenol 
for 10 minutes (Deshpande et al., 2008).  A greater accumulation of cAMP was seen in β-
arrestin2 knock out cells in comparison to wild type cells treated with the same 
isoproterenol (Deshpande et al., 2008). However this short duration study was unable to 
measure time to desensitization for each cell treatment (Deshpande et al., 2008).  
The binding of β-arrestin to the β-AR begins the process of internalization, as β-
arrestins are vital to the trafficking of β-AR to intracellular vesicles for degradation or 
recycling (Shenoy et al., 2001; Reiter and Lefkowitz, 2006). Specifically, these β-
arrestins act as scaffolding proteins to bind proteins responsible for the movement of a 
specific β-AR (Ma and Pei, 2007). The majority of β-AR are internalized through clathrin 
mediated vesicles that form clathrin-coated pits on the plasma membrane awaiting the 
arrival of phosphorylated β-AR-β-arrestin complexes (Reiter and Lefkowitz, 2006). Both 
clathrin and adaptor protein 2 interact with β-arrestins for this specific route of 
endocytosis (Laporte et al., 2000). Clathrin binds to a conserved motif, while adaptor 
protein 2 interacts with arginine 394 and 396 on the carboxyl-terminal tail of β-arrestin 
(Laporte et al., 2000). However, through florescence microscopy of HEK293 cell β-AR-
β-arrestin complexes lacking the clathrin binding motif it has been demonstrated that 
clathrin binding is not important for translocating these complexes to clathrin-coated pits 
for endocytosis (Laporte et al., 2000). The formation of a vesicle from these clathrin-
coated pits is mediated by the GTPase dynamin that pinches the edges of the plasma 
membrane together to form the vesicle (Zhang et al., 1996). In the case of class A 
receptors such as β2-AR, β-arrestin is only loosely associated with the receptor at the 
plasma membrane and dissociates into the cytosol following the formation of clathrin-
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coated vesicles (Oakley et al., 1999; Zhang et al., 1999). Although studied extensively, a 
comprehensive understanding of how β-AR-β-arrestin complexes relocate to the clathrin-
coated pits for endocytosis is unclear.  
Once engulfed in an intracellular vesicle, phosphorylated β-AR are 
dephosphorylated by a membrane associated phosphatase (Krueger et al., 1997). Prior to 
the association of phosphatase to the phosphorylated receptor, the pH of the vesicle 
becomes acidic leading to a conformational change to the β-AR allowing the phosphatase 
to interact (Krueger et al., 1997). The acidic nature of the vesicle is vital for 
dephosphorylation as phosphorylated β-AR treated with NH4Cl halted the 
dephosphorylation and thus re-sensitization of these receptors (Krueger et al., 1997). 
Following the dephosphorylation of these β-AR, they are returned to the plasma 
membrane as functional receptors (Pippig et al., 1995). However, not all β-AR are 
recycled, some are degraded (Shenoy et al., 2001). Chronic desensitization of β-AR can 
be overcome with the help of β-arrestins trafficking unrecyclable β-AR to intracellular 
vesicles for degradation so new receptors can be synthesized (Shenoy and Lefkowitz, 
2003). Whether a β-AR will be recycled or degraded is also affected by the duration of 
BA exposure; the longer the exposure the more likely β-AR will be degraded rather than 
recycled (Shenoy et al., 2001). The duration effect is a limiting factor in the use of BA in 
cattle and is the reasoning behind the feeding of BA for only the final 28 to 42 days on 
feed.   
Phosphodiesterase 
 In addition to GRK and β-arrestin regulation, β-AR activity is also mediated 
through phosphodiesterases (PDE) which are responsible for degrading intracellular 
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cAMP (Shakur et al., 2001). High intracellular concentrations of cAMP can only be 
obtained through the activation of adenylyl cyclase or the inhibition of PDE (Hamza and 
Zhan, 2009). As a secondary messenger in the BA pathway, cAMP binds to the R subunit 
of PKA with high affinity through salt bridges and H bonds (Krishnamurthy et al., 2014). 
The only known means of dissociating cAMP from PKA to recycle back to the inactive 
holoenzyme is through PDE regulation (Wang et al., 2007; Hamza and Zhan, 2009). This 
cAMP dissociation from PKA is in addition to degradation of free cytosolic cAMP further 
preventing the activation of substrates such as PKA (Conti and Jin, 1999; Shakur et al., 
2001). Within the PDE family there are 11 varieties that are specific to substrate and appear 
to be selectively located to specific tissues (Omori and Kotera, 2007). Varieties known for 
the hydrolysis of cAMP include PDE4, PDE7, and PDE8 (Shakur et al., 2001; Omori and 
Kotera, 2007). Additionally, PDE1, PDE2, PDE3, PDE10, and PDE11 are capable of 
hydrolyzing both cAMP and cGMP with the remainder of the 11 PDE proteins only 
equipped for the hydrolysis of cGMP (Shakur et al., 2001; Omori and Kotera, 2007). 
Further, PDE3 and PDE4 varieties appear to be most relevant to a BA response in cattle as 
PDE3 varieties are found in adipocytes and PDE4 is the largest family of PDEs expressed 
highly in most tissues (Beavo, 1995).  
 The structure of PDE is fairly conserved across family members with the C-
terminal sequence having 20 to 45% homology between PDE families and up to 80% 
homology within a PDE family (Francis et al., 2000). In contrast to the conserved C-
terminal, the N-terminal domain of each PDE family is distinct and regulates the activity 
of these proteins (Handa et al., 2008; Maurice et al., 2014). Within the C-terminal lies the 
catalytic domain (Francis et al., 2000). The catalytic domain of PDE4 is comprised of 17 
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α helices split into three subdomains (Xu et al., 2000). The first of these subdomains has 
the N-terminal tail and is a bundle of H3, H5, H6, and H7 with two short helices (H2 and 
H4) interconnecting these (Xu et al., 2000). In addition, this first subdomain also contains 
H0 and H1 which are poorly conserved across PDE families implying that their presence 
is not pertinent to catalytic function (Xu et al., 2000). The second subdomain is much 
smaller, consisting of only two short α helices (H8 and H9) that sit perpendicular to the 
antiparallel α helices H10 and H11 (Xu et al., 2000). Lastly, the third domain includes α 
helices H12, H13, H14, H15, and H16 (Xu et al., 2000). This subdomain is recognized by 
its β hairpin loop that extends between H12 and H13 as well as the partially conserved 
proline 453 residue forming a kink within the H15 helix and the C-terminal tail (Xu et al., 
2000).  
 The deep binding pocket lies within the third subdomain and extends to incorporate 
both the first and second subdomains (Xu et al., 2000). Interestingly, 21 residues are fully 
conserved throughout all PDE families, 20 of these are positioned near this pocket, while 
12 of them are directly in this binding pocket (Xu et al., 2000; Hamza and Zhan, 2009).  
As PDE4 is known to bind cAMP, the atomic structure of PDE4 shows that only this pocket 
is large enough to house the secondary messenger and its degraded product, AMP (Xu et 
al., 2000). The pocket itself is lined with hydrophobic and negatively charged residues and 
contains two divalent metal binding sites at the bottom (Xu et al., 2000; Hamza and Zhan, 
2009). These metal atoms have been identified as Zn2+ and Mg2+ and are held in place by 
residues from all three subdomains (Hamza and Zhan, 2009). The Zn2+ residue helps to 
stabilize the structure of the catalytic domain locking the three subdomains together (Xu et 
al., 2000). Additionally, the Zn2+ metal binding site contains two conserved histidine and 
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aspartic acid residues that are part of a signature recognition sequence (Hamza and Zhan, 
2009). Further, the deletion of the first 298 amino acids in the N-terminal determined that 
Mg2+ is located in the catalytic domain and not on the N-terminal as this deletion still 
elicited Mg2+ dependent PDE activity  (Alvarez et al., 1995). It has since been observed 
that both Mn2+ and Co2+ can be just as effective in this catalytic role (Francis et al., 2000). 
 In addition to the direct regulatory role PDE plays in intracellular messaging, PDE4 
specifically has been recruited by β-arrestin to β2-AR for the control of PKA at the 
membrane because phosphorylation of β-AR by PKA switches its predominant coupling 
from Gs to inhibitory Gi protein (Baillie et al., 2003). This control of PKA ties back to the 
ability of PDE to deactivate PKA by degrading the bound cAMP as noted previously so 
the attenuated β-AR signal can proceed (Wang et al., 2007; Hamza and Zhan, 2009). In a 
negative feedback loop fashion, the phosphorylation of PDE4 on the N-terminal by PKA 
leads to the activation of PDE in rats  (Sette and Conti, 1996). Specifically the serine 54 
residue in the N-terminal is vital to the phosphorylation of PDE4 in rats as the substitution 
of this serine residue with alanine proved unfruitful (Sette and Conti, 1996). This 
mechanism leads to a tight regulation of PKA in the cell. The recruitment of PDE by β-
arrestin to sites of high PKA activity in HEK293 cells provides further evidence for this 
PDE and β-arrestin relationship (Perry et al., 2002).  In addition to the activation of PDE 
through phosphorylation by PKA, PDE can be activated through Ca2+/calmodulin binding 
to specific sites on the N-terminal (Francis et al., 2000). Between PDE families the N-
terminal provides unique activation sites that are responsible for the direct function of the 
specific enzyme (Houslay et al., 2007). These unique sites range from Ca2+/calmodulin 
binding sites in PDE1 to more common PKA phosphorylation sites in PDE3 and PDE2 
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isoenzymes (Francis et al., 2000). The differences in activation and regulation between 
PDE families is most likely dependent on location, although overall function of PDE 
remains focused on hydrolysis of cAMP or cGMP. Through the hydrolysis of cAMP, PDE 
is a potent inhibitor of the β-AR signaling cascade in addition to regulation through β-
arrestins. Although thought of as separate pathways of regulation, review of both families 
of proteins reveal that both PDEs and β-arrestins work together to modulate β-AR 
signaling. These proteins provide tight regulation of secondary messenger signals. In the 
absence of such homeostatic measures secondary messengers such as cAMP would lead to 
the over stimulation of some pathways. Specifically, in the BA pathway this prolonged 
stimulation could lead to the depletion of lipid stores due to the activation of hormone 
sensitive lipase mediated through cAMP activated PKA (Beavo et al., 1974; Mersmann, 
1998; Zhang et al., 2012). Subsequently, this could result in loss of body condition and 
furthermore interrupt the supply of lipids for the structural integrity of phospholipid 
bilayers in cells (Dobretsov et al., 1977). Therefore, this regulation is vital to ensure there 
is no over or under stimulation of such potent cell signaling molecules.  
Performance and carcass attributes of beta agonist use 
The previously discussed mechanism by which BA elicit growth responses 
indicate that muscle accretion should be augmented and fat deposition decreased. 
Moreover, the use of BA in feedlot cattle has been shown to improve the efficiency of 
muscle accretion (Johnson et al., 2014). In the feedlot industry both RAC and ZH have 
commonly been used with similar yet distinct results. A meta-analysis of both RAC and 
ZH use in cattle indicates that ZH generally induces a greater performance response than 
RAC (Lean et al., 2014). Live BW of BA-fed cattle increased 8 kg while the ZH cattle 
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maintained more of this weight in HCW averaging 15 kg heavier than control animals 
(Lean et al., 2014). This disproportionate improvement in HCW over live BW in ZH-fed 
cattle is a direct result of an increase in DP of 1.7%; additionally improved DP in RAC-
fed cattle is also observed (Lean et al., 2014). Evidence of lessened fat accretion is 
provided by the 1 mm decrease in back fat thickness of ZH cattle and decreased marbling 
observed in both ZH and RAC cattle (Lean et al., 2014). Considering the potency of ZH 
in comparison to RAC, fat depletion may be more likely to occur intramuscularly before 
back fat is affected as these results would suggest.  
Over the past several years RAC has become the only commercially available BA 
for use in cattle in the United States and is labeled to be fed the last 28 to 42 days of the 
feeding period at 70 to 430 mg·animal-1·day-1 with no withdrawal time. Variations of the 
labeled dose and duration have been examined with the overall consensus that RAC 
improves feed efficiency, final live BW, and HCW (Lean et al., 2014). However, an 
optimum combination of dose and duration may exist. Supplementation of RAC at 200 
mg·animal-1·day-1 during the final 28 days of the feeding period has been shown to 
improve ADG and feed efficiency while also improving the HCW and REA of British, 
Continental crossbred, and Brahman crossbred calf-fed steers, demonstrating that the BA 
response is produced regardless of breed type (Gruber et al., 2007). Additional studies 
have confirmed the improvement of ADG, feed efficiency, and HCW from RAC 
supplementation (Walker et al., 2006; Winterholler et al., 2007), although these 
performance related enhancements are not always observed (Gonzalez et al., 2009; Hales 
et al., 2016). Whether there is a lack in statistical power or biological reasoning behind 
the lack of performance from RAC is unclear. To further understand the BA response of 
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RAC, combinations of RAC dose and duration have been examined to determine a 
potentially optimum feeding protocol. Testing the efficacy of three doses of RAC: 0, 100, 
or 200 mg·animal-1·day-1 with three durations of use: 28, 35, and 42 days were fed to 360 
crossbred steers weighing approximately 545 kg (Abney et al., 2007). Results suggested 
that of these treatments feeding 200 mg·animal-1·day-1 for 35 days provided the most 
favorable performance (Abney et al., 2007). As RAC dose increased, final BW, ADG, 
feed efficiency, and HCW all increased linearly while REA tended to linearly increase 
signifying a dose dependent response to RAC (Abney et al., 2007). Furthermore, as the 
duration of treatment increased, ADG quadratically increased with 35 day ADG showing 
a 14.8% improvement over 28 day ADG, although no further improvement in ADG was 
observed at 42 days on RAC treatment (Abney et al., 2007). In addition, 1,509 crossbred 
steers weighing approximately 530 kg fed either 0, 100, or 200 mg·animal-1·day-1 of 
RAC for 28, 35, or 42 days elicited similar performance results for RAC, although no 
differences in performance or carcass characteristics were observed from duration of 
RAC treatment (Bittner et al., 2016). Although mixed, these results suggest that 
prolonged exposure to RAC may dampen the BA response, which would be indicative of 
desensitization of the BA pathway as previously discussed.  
Hormonal Implants 
 Hormonal implants have been used in cattle production for decades offering 
greater growth rates, improved feed efficiency, and increased muscle deposition in 
comparison to non-implanted animals (Samber et al., 1996; Duckett et al., 1997). With 
approximately 70% of cattle represented by a survey of consulting nutritionists receiving 
a two implant protocol, the opportunity to further improve cattle performance through 
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progress in hormonal implant programs is vast (Samuelson et al., 2016).  There are a 
wide variety of approved implants available for use in cattle ranging from suckling calves 
to finishing cattle in the feedlot. The active ingredients of these implants are variations of 
naturally occurring and synthetic androgens and estrogens, most commonly trenbolone 
acetate (TBA), estradiol (E2), or estradiol benzoate (Montgomery et al., 2001). These 
hormones are often used in combination to allow for additive performance as TBA and E2 
combinations are more effective than either on their own (Frey et al., 1995). This additive 
performance may be a result of the different mode of action each hormone uses to elicit 
muscle deposition.  
Hormonal implant mechanisms of action 
Hormonal implants are known to improve growth as well as feed efficiency, but 
the exact mechanisms by which these occur is yet to be fully understood. It appears that 
both androgens and estrogens elicit their signal through distinct yet similar routes. 
Although the mechanisms of stimulation may be varied, both improve muscle growth. 
Animals are born with a finite number of muscle fibers therefore growth must occur 
through hypertrophy (Mills, 2002). This hypertrophy is a result of DNA accumulation in 
the cell as myoblasts are the primary source of muscle growth (Chen et al., 2005). 
Myoblasts are not always active; when they are in the quiescent state they are called 
satellite cells (Chen et al., 2005). These satellite cells are located between the basal 
lamina and the sarcolemma of the muscle fiber (Moss and Leblond, 1971).  Following 
activation satellite cells become myoblasts that begin to proliferate and differentiate into 
myotubes before fusing with existing muscle fibers (Moss and Leblond, 1971; Chen et 
al., 2005). These satellite cells are thought to make up between 2 and 10% of nuclei 
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within a myofiber and are responsible for the hypertrophy of the individual fiber 
(Thompson et al., 1989).  
It has been observed that satellite cells are more abundant during early 
development when animals are more prone to rapid growth and begin to decline with age 
(Chen et al., 2005). Evidence of this decline has been observed in pigs when nuclei 
accumulation was evident through 80 days postnatal (Swatland, 1977). Following this 
time period nuclei presence began to decline in individual fibers of porcine muscle as 
expected following this period of rapid growth (Swatland, 1977). Additionally, in steers 
fed to different end weights muscle DNA accumulation began to plateau once steers 
reached 360 kg (Trenkle et al., 1978). Further, the lag phase of satellite cells retrieved 
from 12 and 24 month old rats was significantly longer than in cells from 3 month old 
rats, thus growth is not as prolific with age (Dodson and Allen, 1987). Together these 
studies provide evidence that growth rate begins to decline as animals age in part due to 
alterations in satellite cell function.  
Muscle growth can be positively impacted through the use of hormonal implants. 
Culturing of satellite cells isolated from steers implanted with Revalor-S, a combination 
implant (120 mg TBA  and 24 mg E2), revealed that cells from implanted steers 
proliferated more rapidly than satellite cells from nonimplanted steers between 24 and 72 
hours of culture (Johnson et al., 1998a). Interestingly, at 72 hours the satellite cells from 
nonimplanted steers had comparable rates of proliferation to those of implanted steers 
(Johnson et al., 1998a). These data suggest that satellite cells that were exposed to TBA 
and E2 from an implant were activated more quickly than satellite cells from steers that 
were not implanted (Johnson et al., 1998a).  
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Additionally, when steers were implanted with Revalor-S circulating insulin like 
growth factor I (IGF-I) was increased by 6 days after implantation (Johnson et al., 
1998a). It appears that IGF-I is important in both the proliferation and differentiation of 
skeletal muscle myoblasts due to its vast expression in skeletal muscle (Florini et al., 
1996; Layne and Farmer, 1999). Therefore the sustained elevation of IGF-I in circulation 
between day 0 and 40 of implant is consistent with the profuse growth observed during 
this time period (Johnson et al., 1998a). Furthermore, in steers implanted with Revalor-S 
for 40 days longissimus dorsi IGF-I mRNA was 68% greater than in nonimplanted steers 
(Johnson et al., 1998b). Additionally, both E2 (25.7 mg) and combination TBA (120 mg) 
and E2 (25.7 mg) implants resulted in 78 and 65% increases in IGF-I mRNA, respectively 
in longissimus dorsi muscle 28 days after implantation in comparison to nonimplanted 
controls (Pampusch et al., 2008). Thus, the use of hormonal implants for the stimulation 
of satellite cells offers opportunity to further enhance the efficiency at which growth 
occurs.  
Although often administered concurrently with an androgen, E2 can directly 
mediate muscle growth. In proliferating BSC cultures stimulated with 0.01, 0.1, 1, and 10 
nM of E2 IGF-I mRNA increased in a dose dependent manner (Kamanga-Sollo et al., 
2004). Further, steers treated with E2 (25.7 mg) had increased muscle IGF-I mRNA 
expression (Pampusch et al., 2008). These findings again suggest that IGF-I is an 
important factor in hormone mediated growth. The impact of E2 on IGF-I expression is 
thought to be facilitated through G protein coupled receptor 30 that has since been 
renamed as G protein coupled estrogen receptor-1 (GPER-1) because of its direct role 
with E2 (Kamanga-Sollo et al., 2008a; Kamanga-Sollo et al., 2008b; Filardo and Thomas, 
22 
 
2012). However, the treatment of BSC with G1 (100 nM), an antagonist of GPER-1, 
resulted in a significant increase in IGF-I mRNA, but did not affect proliferation after the 
48 hour treatment (Kamanga-Sollo et al., 2008a). Further, the treatment of BSC with 10 
nM of ICI, an E2 receptor inhibitor, did not hinder the E2 stimulation of IGF-I expression, 
but rather when increased to 100 nM for 48 hours resulted in a 93% increase in IGF-I 
mRNA of BSC (Kamanga-Sollo et al., 2008a). The combined failed repression of IGF-I 
expression through ICI inhibition of the E2 receptor in addition to G1 not being able to 
suppress E2 receptors still suggests that GPER-1 is involved in E2 mediated stimulation of 
IGF-I expression even though G1 suppression of GPER-1 did not yield the expected IGF-
I inhibition (Bologa et al., 2006; Kamanga-Sollo et al., 2008a). One possibility for this is 
the G1 suppression directed E2 to utilize other receptors to elicit the IGF-I response in its 
absence (Kamanga-Sollo et al., 2008a). 
In addition to GPER-1 mediated E2 stimulation of muscle growth, E2 receptor-α is 
believed to provide another mechanism to stimulate hypertrophy. Treating BSC with 
0.001 nM E2 resulted in an increase of E2 receptor-α mRNA by 2.3 times that of control 
treated BSC cultures (Kamanga-Sollo et al., 2004). Interestingly, higher doses of E2 did 
not elicit this increase in E2 receptor-α mRNA (Kamanga-Sollo et al., 2004). Perhaps this 
lack of response in receptors to further E2 stimulation is a mechanism of homeostatic 
regulation. In culture conditions in which E2 treatment does not increase the expression of 
IGF-I or the type I IGF receptor, E2 treatment still stimulates the proliferation of BSC in 
culture (Kamanga-Sollo et al., 2008b). This uninterrupted proliferation of BSC indicates 
that proliferation is stimulated through other receptors such as E2 receptor-α (Kamanga-
Sollo et al., 2008a; Kamanga-Sollo et al., 2008b). Proliferation of BSC due to E2 
23 
 
receptor-α stimulation by E2 was confirmed in BSC cultured in conditions where E2 does 
not stimulate IGF-I mRNA expression (Kamanga-Sollo et al., 2013).  
Additionally, the activation of matrix metalloproteinases 2 and 9 (MMP2/9) may 
be involved in the E2 stimulation of BSC proliferation through the release of heparin 
binding epidermal growth factor-like growth factor (hbEGF) from the cell surface that 
binds to epidermal growth factor receptor (EGFR) mediating the downstream pathways 
that regulate cell proliferation (Filardo et al., 2000; El-Shewy et al., 2004). The inhibition 
of MMP2/9 suppresses E2 stimulated BSC proliferation and supports the hypothesis that 
E2 binding to GPER-1 activates these metalloproteinases resulting in the proteolytic 
release of membrane bound hbEGF and subsequent activation of the EGFR (Kamanga-
Sollo et al., 2014). The MMP2/9 role may go beyond proteolytic release of hbEGF as 
these MMP2/9 are involved in extracellular matrix alterations that are involved in the 
proliferation and impending migration of satellite cells (Montarras et al., 2013).  
Further, protein accretion through satellite cell proliferation is believed to be the 
direct target of androgens due to the expression of androgen receptors on the plasma 
membrane of satellite cells (Doumit et al., 1996). The binding of an androgen to the 
androgen receptor forms a complex that can bind to target genes for the regulation of 
transcription (Chen et al., 2005). However, this ligand bound receptor complex does not 
bind directly to the target gene but rather to androgen response elements (Freedman, 
1992). Specifically, an androgen response element has been verified in the promoter 
region of the IGF-I gene (Wu et al., 2007). This implies that the activation of an androgen 
receptor leads to the production of IGF-I and contributes to the circulating pool of this 
protein. In accordance with this claim, the treatment of BSC collected from the 
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semimembranosus muscle of steers with either 1 or 10 nM of TBA increased IGF-I 
mRNA to 1.7 times that observed in control BSC thereby validating this androgen 
receptor stimulation of IGF-I transcription (Kamanga-Sollo et al., 2004). Furthermore, 
treating BSC with flutamide, an androgen receptor inhibitor, completely repressed the 
ability of TBA (10 nM) to increase IGF-I expression in culture (Kamanga-Sollo et al., 
2008a). Additionally, androgens have been observed to increase the presence of androgen 
receptors in the skeletal muscle of castrated rats when treated with dihydrotestosterone 
(50 mg·kg-1∙day-1 for 7 days; Antonio et al., 1999). Incremental upregulation of androgen 
receptors in porcine satellite cells has been observed with the treatment of 10-7 M 
testosterone for 6, 12, and 24 hours (Doumit et al., 1996). The amplification of androgen 
receptors and IGF-I in response to androgen treatment signifies the importance of these 
receptors in the androgen-containing implant response.  
In addition to androgen receptors mediating the androgen response from hormonal 
implants, androgen activation of a GPCR has been demonstrated to increase muscle 
growth (Heinlein and Chang, 2002). The inhibition of GPCR with GDPβS, a GPCR 
inhibitor, completely suppressed TBA stimulated proliferation of BSC indicating the 
necessity of GPCR to mediate a TBA proliferation response (Thornton et al., 2015). 
Additionally, the individual inhibition of MMP2/9, hbEGF, EGFR, receptor tyrosine 
kinase erbB2, and IGF-I receptor suppressed the TBA-induced stimulation of 
proliferation suggesting that all of these factors are involved in muscle growth through 
the stimulation of satellite cell proliferation (Thornton et al., 2015; Thornton et al., 2016). 
Although protein synthesis rate is impacted by the inhibition of GPCR, MMP2/9, hbEGF, 
erbB2, and IGF-IR protein degradation is not affected by all of these (Thornton et al., 
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2016). Inhibiting EGFR and erbB2 in BSC stimulated with 10 nM of TBA resulted in a 
decrease in the protein degradation rate suggesting the involvement of both EGFR and 
erbB2 in protein degradation (Thornton et al., 2016). These studies suggest that both E2 
and TBA are more similar in their stimulation of BSC proliferation than previously 
thought due to their use of a GPCR and the subsequent activation of MMP2/9 leading to 
EGFR stimulation and therefore increased proliferation of satellite cells.  
Further, it has also been suggested that hypertrophy as a result of TBA stimulation 
involves altering the responsiveness of satellite cells to factors such as IGF-I and 
fibroblast growth factor (Thompson et al., 1989). Through body composition analysis of 
rats treated with a TBA injection (80 μg/ 100 g BW), the weight gain thereafter was a 
result of both muscle and skeletal tissue growth (Thompson et al., 1989). It was further 
found that rats treated with TBA had greater accumulation of DNA per muscle fiber than 
control rats demonstrating the important role satellite cells have in muscle hypertrophy 
(Thompson et al., 1989). Through the evaluation of muscle cells cultured from TBA 
treated rats, it was concluded that these androgen treated rats were more responsive to 
IGF-I and fibroblast growth factor due to their increase in hypertrophy in comparison to 
control rats (Thompson et al., 1989).   
It appears that in addition to androgen, E2, and GPCR receptors the type I IGF 
receptor is involved in the proliferation of BSC. This receptor consists of 2 α and 2 β 
subunits that are conjoined through disulfide bonds (Kamanga-Sollo et al., 2013). The α 
subunits are completely extracellular and contain the IGF binding sites while the β 
subunits transverse the cell membrane and contain a tyrosine kinase domain that is 
essential for receptor function (Steele-Perkins et al., 1988). In E2 stimulated BSC, the 
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treatment of LR3-IFGI (an analogue of IGF-I) with AG1024, an inhibitor of type I IGF 
receptor β tyrosine kinase, resulted in the hindrance of BSC proliferation mediated 
through LR3-IGFI as well as the ability of E2 to stimulate proliferation of BSCs 
(Kamanga-Sollo et al., 2013). Further, type I IGF receptor siRNA is capable of 
completely hindering the stimulatory effects of LR3-IGFI and E2 on BCS proliferation 
(Kamanga-Sollo et al., 2013). These results suggest that type I IGF receptor is vital in the 
ability of E2 to stimulate cell proliferation (Kamanga-Sollo et al., 2013).  
With both androgen and E2 stimulation the secretion of growth hormone (GH) 
from the pituitary gland is also involved in the subsequent growth response (Velloso, 
2008). In order to affect growth, GH stimulates the production of IGF-I both in the liver 
and tissues such as muscle (Velloso, 2008). Production of IGF-I occurs in the liver and 
forms a ternary complex with the binding protein IGFBP-3 and the acid labile subunit for 
transport in the plasma (Fan et al., 2009). This complex allows for the controlled release 
of IGF-I in the plasma for delivery to tissues in need of IGF-I action (Fan et al., 2009). It 
is not fully understood what growth benefits are due to circulating IGF-I or direct GH 
action (Fan et al., 2009). Additionally, IGF-I is responsible for the negative feedback of 
GH as high circulating IGF-I stunts the release of GH from the pituitary gland (Velloso, 
2008). Although in IGF-I knock out mice growth was less restricted in comparison to 
both IGF-I and GH receptor knock out mice, suggesting that growth from GH is also 
mediated through an IGF-I independent pathway (Lupu et al., 2001). Although the 
mechanism for hormonal implant induced growth is not fully understood, it appears that 
each of these receptors and proteins may play a critical role in mediating this growth 
response in a collective manner.  
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Effect of hormonal implant on cattle performance 
 Hormonal implants are known to enhance the growth rate of cattle. A multitude of 
implant strategies can be utilized. Therefore, the specific combination of hormones and 
timing may be of value in determining an implant strategy. In a test of hormone efficacy 
many studies have looked at treatments with only TBA or E2 in comparison to 
combinations of the two. Additionally, studying the effect of hormonal implants on intact 
animals has also improved the understanding of this growth promoting technology. In a 
study of both steers and bulls implanted once with 120 mg TBA,  120 mg TBA and 24 
mg E2, or no implant produced a 22% increase in ADG over control counterparts during 
the growing phase of production (Hunt et al., 1991). However, there was no difference in 
ADG or feed efficiency in steers treated with TBA only (Hunt et al., 1991). Interestingly, 
this combination implant in steers produced an ADG response that was comparable to 
bulls of any treatment (Hunt et al., 1991). The lack of differences between implant 
treatments in bulls is likely due to greater circulating testosterone in comparison to steers 
suggesting that bulls are growing at their maximum rate prior to the administration of 
hormonal implants. Further examination into biological differences in sex hormones was 
conducted in a combination implant study using steers and heifers. The utilization of a 
combination implant with 200 mg TBA and 28 mg estradiol benzoate (Synovex Plus) 
resulted in an overall 36% greater ADG for heifers and 16% greater in steers although 
differences in BW between treatments were not observed until later in the feeding period 
(Smith et al., 2007). These differences between heifers and steers may be specific to this 
trial as in general it appears that steers respond better to hormonal implants than heifers 
due to their higher growth potential.  
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 Although most implants are combinations of both TBA and E2, some less potent 
implants are comprised of E2 only. In steers an E2 only implant (30 mg) has been shown 
to increase ADG by 7% and tended to improve feed efficiency by 3% over non-implanted 
steers (Bartle et al., 1992). However, it is thought these performance results are to some 
extent diluted due to the long duration of both trials that comprised this study (140-168 
days) in comparison to the lasting effects of the E2 implant (Bartle et al., 1992). In 
addition, the benefits of a TBA and E2 combination implant were observed in this study 
where steer performance linearly increased as both hormones were increased from 20 mg 
TBA and 4 mg of E2 to 140 mg TBA and 28 mg E2 (Bartle et al., 1992). The 140 mg TBA 
and 28 mg E2 combination implant was determined to be the most effective as ADG was 
improved by 18% and feed efficiency by 10% over non-implanted controls (Bartle et al., 
1992). Further, steers implanted with Revalor-S (120 mg TBA and 24 mg E2) had 28% 
greater ADG and 23% greater feed efficiency in comparison to nonimplanted steers 
(Johnson et al., 1998b). Interestingly, in yearling steers implanted with 120 mg TBA and 
24 mg E2 ADG and feed efficiency were improved by 18 and 13% in the first 40 days 
following implantation, respectively, while no differences in ADG or feed efficiency 
were observed for the overall 143 day trial (Johnson et al., 1996). Through these studies it 
is established that hormonal implant growth responses are dose dependent and are 
enhanced through the administration of higher doses of both androgens and estrogens.  
As the end-product is of economic concern to producers, understanding the effects 
of hormonal implants on the carcass is vital. In yearling steers implanted with 120 mg 
TBA and 24 mg E2 HCW was improved by 26 kg in steers that were fed to 143 days from 
the time of implantation (Johnson et al., 1996). Additionally, Angus steers implanted with 
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140 mg TBA and 28 mg E2 had a 20 kg advantage in HCW in comparison to 
nonimplanted Angus steers (Perry et al., 1991). Further studies with steers and heifers 
revealed a 21 kg increase in HCW for steers implanted with 200 mg TBA and 28 mg 
estradiol benzoate, implanted heifers only tended to increase HCW (Smith et al., 2007). 
In an effort to determine the effects of implants on carcass traits throughout the feeding 
period steers were serial slaughtered at 40, 115, and 143 days post implantation of 120 
mg TBA and 24 mg E2 (Johnson et al., 1996). At day 40 there were no differences, but by 
day 115 REA was larger for implanted steers while percent kidney pelvic heart fat (KPH) 
was decreased in implanted steers at day 143 (Johnson et al., 1996). This larger REA 
agrees with previous work that showed a linear increase in REA with increased 
combination implant hormone dose as well as a 23% larger REA in heifers implanted 
with a high potency implant (Bartle et al., 1992; Smith et al., 2007). However, this 
incremental increase in hormone dosage also resulted in an linear decrease in marbling 
scores (Bartle et al., 1992). However, marbling scores are not always decreased with 
implants, often feeding implanted cattle up to two weeks longer than nonimplanted cattle 
allows for the fast growing muscle to deposit fat, therefore feeding cattle to a common fat 
cover appears to alleviate any depression in marbling (Johnson et al., 1996; Guiroy et al., 
2002).  
Overall, it appears that use of hormonal implants in beef production results in 
greater performance and feed efficiency especially in the first 40 days following 
implantation. Additionally, a two implant protocol utilizing two combination implants 
results in a 7.5% increase in HCW and 9.0% increase in REA in comparison to 
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nonimplanted control cattle (Duckett and Pratt, 2014). Through the performance benefits 
of utilizing hormonal implants cattle can be grown in a more efficient manner.  
Copper 
The formation of hemoglobin was first noted to be Cu dependent in rats and 
signified that Cu is a vital component to proper biological function (Hart et al., 1928).  
Since this early discovery, Cu has been identified to have a critical role in growth through 
the Cu dependent enzyme lysyl oxidase that is responsible for cross-linking in connective 
tissue and formation of the extracellular matrix (ECM; Rucker et al., 1998). The ECM is 
of great importance in growth as it is composed of both structural and functional proteins 
that are responsible for the integrity of the cell and contributes to cell regeneration and 
tissue development (Gentili and Cancedda, 2009). In addition, Cu is essential for iron (Fe) 
oxidation via the proteins hephaestin and ceruloplasmin (Vulpe et al., 1999; Eisenstein, 
2000; Vashchenko and MacGillivray, 2013). As ferroxidases, both hephaestin and 
ceruloplasmin are crucial to the oxidation of Fe to facilitate Fe passage to the Fe transporter, 
transferrin, to be distributed throughout the body (Cherukuri et al., 2005; Vashchenko and 
MacGillivray, 2013). Without adequate Cu status to support function of these ferroxidases, 
a decrease in hephaestin within cells as well as an increase in Fe concentrations in the cell 
has been observed further indicating that Fe transport has declined due to the critical role 
of Cu in ferroxidases (Suttle, 2010). An antioxidant role has also been associated with Cu 
through its catalytic function in Cu Zn superoxide dismutase in which the Cu molecule is 
partly exposed within the active site for the binding of reactive oxygen molecules (Tainer 
et al., 1983). One of the more easily visualized functions of Cu in the body is its role in 
tyrosinase to convert tyrosine to melanin (Suttle, 2010). The improper function of 
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tyrosinase results in the depigmentation of hair follicles resulting in the speckled gray 
patches of hair often seen near the eyes of severely Cu deficient cattle (Suttle, 2010). The 
many roles of Cu in the body clearly indicate the importance of this mineral on biological 
functions. 
Copper absorption and trafficking  
Copper absorption in the enterocyte is mainly facilitated through the transport 
protein CTR1 on the apical membrane as demonstrated by a decrease in Cu accumulation 
in peripheral tissues and poor growth in transgenic mice lacking intestinal epithelial cell 
CTR1 (Nose et al., 2006). The reliance on CTR1 is further indicated by resorption of CTR1 
knockout mice embryos, signifying that the absence of CTR1 is embryonically lethal  (Lee 
et al., 2001). Structurally, CTR1 is made up of three transmembrane domains as discovered 
through hydropathy analysis of the gene sequence (Eisses and Kaplan, 2002). These 
domains are fairly conserved across species with transmembrane domain 1 having the most 
variability (Puig et al., 2002). Imaging of CTR1 further expanded understanding of the 
transport protein by indicating that CTR1 is a trimer with each monomer consisting of three 
transmembrane domains to form a pore for Cu transport through the plasma membrane 
(Aller and Unger, 2006). This discovery implies that CTR1 more closely resembles a 
channel rather than a transport protein.  
The extracellular portion of the protein is considered the N-terminal or ecto-
domain, whereas the cytosolic portion is the C-terminal (Ohrvik and Thiele, 2014). As a 
transport protein, CTR1 is responsible for the uptake of Cu into the enterocyte as 
discovered in work focused on the biological function of both mouse and human CTR1 
(Lee et al., 2000; Lee et al., 2002a). This singular directional movement of Cu indicates 
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that the extracellular and cytosolic terminals must be specific to this pull of Cu into the 
cell. Genetic analysis of Cu transport proteins across yeast, mice, and humans indicated 
that the N-terminal has three to five methionine motifs arranged as MXXM or MXM; 
where M represents methionine and X any amino acid (Puig et al., 2002). In 
Saccharomyces cerevisiae CTR1, the last methionine before transmembrane domain 1 is 
labeled methionine 127; to analyze the importance of this methionine, it was replaced with 
cysteine or serine resulting in significant decreases in Cu absorption (Puig et al., 2002). 
The decline in Cu absorption suggests that methionine 127 is integral in the coordination 
of Cu transport through CTR1. The N-terminal of human CTR1 is comprised of known Cu 
ligands methionine and histidine as well as serine (Zhou and Gitschier, 1997). The 
abundance of Cu ligands suggests that methionine and histidine may be essential in 
scavenging for Cu to import. On the cytosolic side of the plasma membrane, the C-terminal 
of yeast CTR1 is composed of two cysteine-X-cysteine motifs (Xiao and Wedd, 2002). The 
energetics of Cu passage, although not fully understood, have been evaluated. Cell culture 
work has indicated that Cu movement through CTR1 is ATP independent and is unaffected 
by an inhibitor of Na+/K+ ATPase (Lee et al., 2002b). This suggests Cu uptake through 
CTR1 is passive.  
In addition to CTR1, the Fe2+ transporter divalent metal transporter 1 (DMT1) was 
evaluated for its ability to transport Cu across the apical membrane of enterocytes. Utilizing 
Caco-2 cells in ascorbate infused medium, DMT1 transported Cu across the apical 
membrane (Arredondo et al., 2003). The addition of ascorbate to the medium was utilized 
from preliminary data that suggested Cu could not be transported through DMT1 without 
a change in oxidation state. The successful transport of Cu through DMT1 in the presence 
33 
 
of ascorbate indicates that Cu is in the reduced state (Cu1+) due to the reducing power of 
ascorbate. In addition, Cu was also noted to be increasingly transported through DMT1 in 
Fe deficient rats (Jiang et al., 2013). These studies indicate that Cu can indeed be 
transported by DMT1, but also that Cu transport can be affected by the presence of other 
minerals. 
Following absorption through the apical membrane of both the enterocyte and 
hepatocyte, Cu is met with chaperones to further distribute the mineral throughout the cell 
to fulfil Cu dependent functions and proteins. The two cysteine residues of the CTR1 C-
terminal may be integral in the transfer of Cu1+ from CTR1 to the chaperone protein (Xiao 
and Wedd, 2002). Copper is capable of damaging proteins, lipids, and nucleic acids due to 
its redox potential in which an accumulation of unbound Cu can lead to the formation of 
oxygen radicals (Rosenzweig et al., 1999; Gaetke and Chow, 2003). The use of chaperone 
proteins minimizes the risk of potential harm to the cell by ensuring that the Cu molecule 
is escorted through the cell at all times. There are three chaperone proteins that are essential 
for Cu intracellular transport, including CCS, Cox17, and Atx1.  
The Cu chaperone for SOD (CCS) transports Cu from the CTR1 C-terminal to Cu, 
Zn SOD1 (Casareno et al., 1998). Three domains make up the chaperone, each with distinct 
features. Domain I is considered the amino-terminal region with a Cu binding site similar 
to the Cu chaperone Atx1 (Rosenzweig et al., 1999). Although equipped with a Cu binding 
site, domain I Cu binding is only necessary under conditions of severe deficiency (Schmidt 
et al., 1999). Domain II of CCS is somewhat homologous to SOD1, through yeast cell 
testing this domain appears to have a role in forming a complex with SOD1 to facilitate the 
transfer of Cu (Schmidt et al., 2000). Further experiments with yeast cells indicate that 
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domain II is important for interacting with SOD1, but not capable of transferring Cu on its 
own (Schmidt et al., 2000). The final portion of CCS, domain III, has a CXC copper 
binding site that is required for the transfer of Cu from the chaperone into the SOD1 
structure as noted in vivo with yeast CCS (Schmidt et al., 1999). Considering domain I is 
limited to Cu binding during periods of Cu deficiency, domain III would be the primary 
binder of Cu to thus interact with SOD1.   
The first evidence of the Cu chaperone Cox17 was discovered in yeast cells with 
defective cytochrome c oxidase, determined to be caused by a mutation in the Cox17 gene 
(Glerum et al., 1996a). Cytochrome c oxidase is located in the inner membrane of the 
mitochondria and is comprised of 13 subunits (Tsukihara et al., 1996). The enzyme has 
two Cu centers, CuA and CuB, in which three Cu ions are necessary for function of the 
enzyme and thus the respiratory chain (Tsukihara et al., 1996). Upon binding Cu from 
CTR1, Cox17 transports Cu to the intermembrane space of mitochondria where it transfers 
Cu to both Sco1 and Cox11 (Horng et al., 2004). Following the transfer of Cu ions from 
Cox17, Sco1 and Cox11 provide Cu to the CuA center in Cox2 and the CuB center in Cox1 
of cytochrome c oxidase, respectively (Horng et al., 2004). In addition to the protein Sco1, 
Sco2 has been noted to have overlapping functions, but is not homologous to Sco1 
indicating that both are needed for proper Cu incorporation into cytochrome c oxidase 
(Glerum et al., 1996b).  
In addition to CCS and Cox17, Cu imported through CTR1 can also bind to the Cu 
chaperone Atx1/Atox1 through a bond with two cysteine residues and a sulfur atom of the 
Atx1 molecule for secure transport (Pufahl et al., 1997). The human homologue to Atx1, 
is HAH1, and its function is conserved across cell type (Hamza et al., 1999). The Atx1 Cu 
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loaded molecule diffuses through the cytoplasm of the hepatocyte to the target ATP7B  
ATPase located on the golgi apparatus where it interacts with the cytosolic Atx1-like 
domains (Klomp et al., 1997; Hung et al., 1998). Further, the import of Cu into the trans 
golgi network leads to the activation of Ceruloplasmin (Cp), a multi-Cu ferroxidase 
(Terada et al., 1995). Upon binding to the golgi apparatus, Cu is transported down a 
thermodynamic gradient produced by the ATPase ATP7A or ATP7B in enterocyte or liver 
cells, respectively (Pufahl et al., 1997). Specifically, ATP7A has been found through 
fluorescent imaging to localize to the trans golgi network to accumulate Cu and then move 
to the plasma membrane when cellular Cu is high for the efflux of Cu out of the enterocyte 
(Petris et al., 1996). This indicates that the P-type ATPases are important in the transport 
of Cu to the portal vein for further compartmentalization in the liver.  
Liver absorption of Cu from the portal vein is similar to the enterocyte with the 
exception that a metalloreductase is not necessary considering Cu is already in the reduced 
state (Kim et al., 2008).  The aforementioned Cu chaperones CCS, Cox17, and Atx1 bind 
to free Cu as it enters the cell to direct the Cu to specific cuproproteins or pathways (Glerum 
et al., 1996a; Lutsenko, 2010). In addition to Cu Zn SOD, cytochrome c oxidase, and Cp 
among others, Cu can be stored within the hepatocytes bound to the protein metallothionein 
which can hold 11 to 12 Cu ions at one time (Luza and Speisky, 1996). The role of 
metallothionein in the liver goes beyond temporary storage for cytoplasmic Cu, it 
alternatively is a protective mechanism from Cu-induced cytotoxicity (Linder and Hazegh-
Azam, 1996; Luza and Speisky, 1996). This protective system may be why metallothionein 
has a greater affinity for Cu than either Cd or Zn and the release of Cu from the storage 
protein requires extremely low pH values (Luza and Speisky, 1996). Further information 
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on the mobilization of Cu from metallothionein storage during a time of deficiency is 
limited with more in-depth work needed to understand this mechanism. 
As Cu needs of the body are met, excess Cu must be released to avoid over 
accumulation of the metal; biliary excretion represents the majority of Cu removal (Luza 
and Speisky, 1996). This biliary excretion is facilitated through ATP7B moving from the 
trans-Golgi network to lysosomes when Cu concentrations are high; ATP7B is responsible 
for the transport of Cu into lysosomes for further release into the bile canaliculus powered 
by ATP hydrolysis (Polishchuk et al., 2014; Ogórek et al., 2017). In Wilson’s disease 
ATP7B is impaired or absent, thus resulting in the build-up of Cu within hepatocytes as 
ATP7B is the only known means of Cu export (Poujois et al., 2017). Both metallothionein 
and reduced glutathione (GSH) bind free Cu+, this may in part be a mechanism to cope 
with an increase in hepatocyte Cu concentrations (Luza and Speisky, 1996; Aliaga et al., 
2016). As the available metallothionein and GSH reserves are depleted, the hepatocytes 
experience oxidative stress leading to cell apoptosis (Zischka and Lichtmannegger, 2014). 
Free Cu released from the cells binds to serum albumin, as free Cu in the body is dangerous, 
and travels to the brain, eyes, and occasionally the kidneys and heart where it will 
accumulate (Zischka and Lichtmannegger, 2014). This accumulation in the eyes, known as 
the Kayser-Fleischer ring, is seen in approximately 99% of Wilson’s disease patients, 
although less severe or early stages of the disease may only result in increased hepatic 
concentrations of Cu (Brewer, 2000; Liu et al., 2002). 
 In addition to metallothionein’s role in prevention of cytotoxicity from Cu, GSH 
can function as both a nucleophile as well as a reductant in an effort to protect nucleic acids 
and protein from harmful interactions with free Cu (Freedman et al., 1989; Hanna and 
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Mason, 1992; Pompella et al., 2003). Most functions of GSH are related to the thiol group 
of the protein acting as a reductant as noted in plant cell work, further exemplified by GSH 
having the greatest intracellular availability of cysteine residues for the binding of Cu  
(Nagalakshmi and Prasad, 2001; Aliaga et al., 2016). This tripeptide is mainly expressed 
in the cytosol, accounting for 80 to 85 percent of cellular expression, while also having an 
antioxidant role within the mitochondria (Aliaga et al., 2016). The antioxidant capacity of 
GSH is diverse, it can either scavenge for reactive oxygen species or serve as a substrate 
for glutathione transferase enzymes during the conjugation of potentially pro-oxidant 
molecules (Deponte, 2013). Furthermore GSH is a cofactor for glutathione peroxidase that 
specifically reduces the reactive oxygen species hydrogen peroxide and lipid peroxides 
resulting in the oxidized form GSSG (Aliaga et al., 2016). The ratio of GSH and GSSG 
within the cell is of great importance for the redox potential as a high GSH:GSSG ratio is 
necessary for optimum protein synthesis (Nagalakshmi and Prasad, 2001). Regardless of 
the redox state, both GSH and GSSG are capable of forming complexes with Cu; although 
GSH tends to form compounds more readily due to its greater intracellular concentration 
(Aliaga et al., 2016). The study of the Cu reaction with GSH has led to the understanding 
that one Cu+ ion is bound to two GSH molecules to form a stable Cu (I)- [GSH]2 complex 
(Aliaga et al., 2016). This complex may be an important component of Cu acquisition from 
the Cu transport protein Ctr1. Through the utilization of HEK293 cells treated with L-
buthionine-sulfoximine for the reduction of cellular GSH, it has been demonstrated that the 
rate of Cu influx is dependent upon GSH as the initial rate of Cu entry into the cell declined 
under these conditions of low GSH (Maryon et al., 2013). The slowed rate of Cu entry was 
reversed by the supplementation of GSH to the cell, indicating that GSH may have a role 
38 
 
in the acquisition of Cu from Ctr1 (Maryon et al., 2013). This finding changes our current 
understanding of intracellular Cu trafficking. It has been assumed that Cu chaperones CCS, 
Cox17, and Atx1 directly interact with Ctr1 to acquire Cu, although this study reveals that 
these chaperones may in fact rely on GSH to load Cu for intracellular trafficking (Maryon 
et al., 2013). 
Ceruloplasmin 
It appears that Cp has many functions including Cu transport, antioxidant 
capabilities, amine oxidase activity, and most notably is a multi-Cu ferroxidase with a role 
in Fe mobilization (Zaitseva et al., 1996). Ceruloplasmin belongs to a family of multi-Cu 
oxidases including ascorbate oxidase and laccase that all have three spectroscopically 
different forms of Cu: type I, type II, and type III (Askwith et al., 1994). X-ray imaging of 
human serum Cp at 3.1 Å revealed that the protein is comprised of six domains arranged 
in a triangular formation (Zaitseva et al., 1996). Through comparison to family member 
protein ascorbate oxidase, the six domains were detected to be linked by disulfide bridges 
in accordance with structural similarities to ascorbate oxidase (Messerschmidt and Huber, 
1990). Further, the x-ray crystallography of the holo protein indicated the six domains were 
comprised of three homologous regions that were made up of two parts each (Linder, 
2016). Six to eight Cu ions are associated with the structure of Cp, six of which bind to the 
major Cu binding sites across the six domains (Sato and Gitlin, 1991). Within Cp there are 
three type I Cu binding sites at which a transfer of charge between S and Cu results in the 
intense blue coloration of the protein (Hellman and Gitlin, 2002). These type I Cu-binding 
sites have a cysteine, two histidine amino acids, and a methionine as ligands for Cu on 
domains IV and VI (Zaitseva et al., 1996). On domain II, the methionine is substituted with 
39 
 
a leucine residue analogous to fungal laccases (Zaitseva et al., 1996; Bento et al., 2007). 
Only one type II Cu binding site is represented on the protein in addition to two type III 
Cu binding sites (Hellman and Gitlin, 2002). The type II and III Cu binding sites are close 
together forming a trinuclear type II-type III Cu cluster that is important in the redox 
properties of Cp (Calabreses et al., 1983).  
In addition to the six major Cu binding sites, Cp is also host to two metal ion-
binding sites on the protein surface of domains IV and VI and are home to the oxidation of 
Fe, Cu, and Co upon binding (Bento et al., 2007; Lindley et al., 1997).  In observance of 
rat Cp a new metal ion-binding site was discovered on domain II with three protein ligands, 
histidine 290, aspartic acid 292, and lysine 512 acting in coordination with a molecule of 
water to bind Cu to the labile site (Samygina et al., 2017). This newly found labile Cu 
binding site is found on only three other species not including human or bovine Cp and is 
likely the result of a single amino acid substitution as human Cp has a leucine in place of 
the histidine found in the new binding site (Samygina et al., 2017). This single substitution 
of amino acid residues indicates that Cp is variable between species and with better 
resolution imaging to come further understanding of the intricate Cp protein will be 
learned. In addition, a Ca2+ binding site on domain I was confirmed through the improved 
resolution of x-ray imaging (Bento et al., 2007). The interaction between Cp and red blood 
cells is a Ca2+ dependent process in which the binding of Cp to the plasma membrane of 
the red blood cell is the limiting step thought to be mediated by Ca2+ (Saenko and 
Yaropolov, 1990). Furthermore, the rigid structure of human Cp is in part due to the 
discovery of Na+ at the base of each pair of domains (Bento et al., 2007). In addition to the 
new labile Cu binding site, it was also found that Zn can bind to major Cu binding sites as 
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picked up by x-ray fluorescence at a rate of 40-50% substitution (Samygina et al., 2017). 
However, 100% substitution of Cu by Zn at the six major binding sites rendered the protein 
inactive in both in vivo and in vitro studies (Samygina et al., 2017). 
 As aforementioned, the role of Cp as a ferroxidase is amongst the most prominent 
functions of this protein. Indication of potential ceruloplasmin activity to oxidize Fe from 
the ferrous (Fe2+) to ferric (Fe3+) form was found in serum samples (Osaki et al., 1966; 
Roeser et al., 1970). This transformation makes Fe available to be bound to the Fe 
transport protein transferrin for transport through the serum (Aisen et al., 2001). The 
importance of the ferroxidase activity of Cp is further indicated by the accumulation of 
Fe in the basal ganglia of the brain as seen in a hereditary Cp deficiency of Japanese 
siblings (Morita et al., 1995). In addition, the administration of Cp to Cp knockout mice 
resulted in improved Cp concentration with restored ferroxidase activity leading to the 
disappearance of accumulated Fe in the brain (Zanardi et al., 2018).  
 An acute phase response is elicited by acute phase proteins such as Cp that act as 
part of host defense system against stress, inflammation, trauma, or infection (Cray et al., 
2009). Ceruloplasmin’s role as an acute phase protein has been documented in many 
species. Feed deprivation in broilers elicited an acute phase response that included an 
increase in Cp after 30 hours (Najafi et al., 2016). A positive correlation between fasting 
glucose and Cp was found in a case study enrolling initially healthy men and women in 
Sweden while recording blood parameters throughout their lives following a diabetes 
diagnosis, but no direct link between Cp and diabetes was detected (Muhammad et al., 
2016). Further, Cp has been shown to mimic superoxide dismutase by inhibiting the 
reduction of ferricytochrome c and other lipid bound molecules (Goldstein et al., 1979). 
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An acute phase response can result in a 2- to 3-fold increase in Cp in response to a 
stressor  (Giurgea et al., 2005). Although functioning as an acute phase protein Cp has a 
substantially lower oxygen radical scavenging activity in comparison to circulating 
superoxide dismutase (Goldstein et al., 1979). Taken together these studies indicate that 
Cp does have a role in acute phase responses, but to what degree is yet to be determined.     
A link between estrogen and the Cu dependent protein Cp has been known since 
the 1960’s when estrogenic oral contraceptives were shown to increase circulating Cp 
(Carruthers et al., 1966). Later the connection between Cp and estrogen was discovered 
to be independent of liver Cu status as mice fed a diet high in antagonistic Zn still 
secreted Cp, regardless of low liver Cu status (Evans et al., 1970). Injecting male and 
ovariectomized female rats with 50 μg/day of estradiol-17β for up to 42 days revealed 
increases in both serum Cp and Cu that began to plateau after 28 days of injections 
(Sunderman et al., 1971). Further increasing the dose of estradiol-17β to 140 μg/day led 
to a slow rise in serum Cp concentrations that were 70% greater than control rats on day 
7 and almost 3 times as great on day 14 (Middleton and Linder, 1993). Moreover, the 
study of mammary epithelial cells in differing concentrations of Cu medium and at 
varying states of cellular differentiation: resting, lactating, and suckling, indicate that Cp 
transcription and secretion is increased in lactating and suckling cells (Freestone et al., 
2016). This increase in both apo and holo Cp during lactation and suckling is understood 
to be a hormonal response present when Cu concentrations were adequate (Freestone et 
al., 2016). This increase in circulating Cp in response to estradiol-17β suggests that the 
Cu requirement of the animal may be increased due to the estradiol-17β treatment 
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providing a possible linkage between Cu supplementation and hormonal implant use in 
livestock production.  
Lysyl oxidase  
Lysyl oxidase (LOX) is most notably known for its ability to catalyze covalent 
cross-linking structures within the ECM (Zhang et al., 2015). The oxidative function of 
the protein modifies the ε- amino groups of lysine side chains in both collagen and elastin 
to aldehydes (Oldfield et al., 2018).The reactive aldehydes left behind form covalent 
crosslinks with nearby amines and other aldehydes, thus stabilizing the collagen and 
elastin fibers within the ECM (Smith-Mungo and Kagan, 1998). The catalytic function of 
LOX is Cu dependent as the removal of Cu with a high urea concentration and use of a 
Cu chelator inhibited LOX activity (Gacheru et al., 1990). In addition to dependence on 
Cu, LOX catalytic domain requires a quinone component, lysyl tyrosylquinone for 
catalytic function (Wang et al., 1996). The incorporation of both Cu and a quinone into 
the protein for catalytic function link the LOX family with the Cu amine oxidase family 
with the proposed mechanism for LOX based on this family of proteins (Finney et al., 
2014; Moon et al., 2014). However, sequence analysis of both protein families indicate 
there is no obvious homology (Zhang et al., 2018); indicating that the LOX mechanism of 
action may be distinct from the Cu amine oxidase family.  
Within the LOX family there are four LOX like proteins (LOXL1-4) of which the 
Cu-binding and catalytic domains are highly conserved (Csiszar, 2001). Limited 
structural analysis of LOX has led to a better understanding of protein function through 
the combination of structural knowledge from each protein type within the family. These 
LOX proteins have three conserved histidine residues within their catalytic site, which 
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are believed to be the binding site of Cu2+ (Moon et al., 2014). These three conserved 
histidine residues are thought to form an octahedral configuration with Cu2+ within the 
catalytic domain (Gacheru et al., 1990). Further work utilizing a 3-point mutation 
model and gene recombination found that of these histidine residues histidine 303 is the 
catalytic base of LOX proteins (Oldfield et al., 2018). The incorporation  of other amino 
acid residues in place of histidine 303 yielded negative results as no Cu incorporation or 
lysyl tryosylquinone formation was detected (Oldfield et al., 2018). 
 Differences between the LOX family proteins arise from structural components. 
Both LOX and LOXL1 contain an N-terminal pro-peptide, which is removed through 
proteolytic cleavage in the ECM during protein maturation (Moon et al., 2014). Further, 
LOXL2-4 each consist of 4 scavenger receptor cysteine-rich (SRCR) domains which are 
believed to facilitate exchanges between ECM proteins  (Hohenester et al., 1999). The 
cysteine dense nature of these domains and the catalytic domain has created difficulties in 
the structural analysis of LOX proteins (Moon et al., 2014). However, human LOXL-2 
(hLOXL-2) protein has been extensively analyzed in a Zn bound precursor state in which 
the catalytic domain has been shown to have both a core and extra segments (Zhang et 
al., 2018). The core is comprised of three β-sheets; two smaller and one larger in which 
disulfide bonds stabilize the structure (Zhang et al., 2018). The extra segments surround 
the core of the catalytic domain with only one segment linked to the core through a bent 
α-helix link and a disulfide bridge (Zhang et al., 2018). Another extra segment has a β-
hairpin structure that accommodates the highly conserved Cu-binding motif and is linked 
by a disulfide bridge to the first extra segment for stability (Zhang et al., 2018). Further 
the overall structure of hLOXL-2 was found to be triangular in nature with SRCR3, 
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SRCR4, and the catalytic domain each making up a corner of this structure (Zhang et al., 
2018). The SRCR3 domain is linked to the catalytic domain through hydrogen bonds 
while the SRCR4 domain does not have direct contact with the catalytic domain (Zhang 
et al., 2018) Further distinctions between LOX proteins may be their predominant tissue 
expression. The LOXL-3 gene when first isolated was found in the heart, liver, smooth 
muscle, kidney, pancreas, and brain (Jourdan-Le Saux et al., 2001). Through 
immunofluorescence staining, LOXL3 was found primarily in the palate and tongue of 
mice (Zhang et al., 2015). This finding was verified when LOXL3 knock out mice were 
born with cleft palates and some with spinal deformities (Zhang et al., 2015).  
The LOX family of proteins can be regulated through various biological factors. 
The removal of Cu was thought to render the enzyme inactive, but interestingly mature 
LOX depleted of Cu was found to maintain around half of its catalytic function (Tang 
and Klinman, 2001). The collagen associated protein fibromodulin directly influences site 
specific collagen cross-linking (Kalamajski et al., 2016). Furthermore, fibromodulin has 
also been shown to increase enzymatic activity of LOX, indicating the importance of this 
protein in LOX  regulation (Kalamajski et al., 2016). In addition, estrogen has been 
shown to decrease LOX activity when engineered ligament sections were treated with 
physiologically high doses of 17β-estradiol (500 pg/ml) for 24 to 48 hours (Lee et al., 
2015). This estrogen response appears to affect the ability of present LOX to effectively 
form cross-links within the collagen, understanding of how this estrogen response occurs 
is awaiting further research (Lee et al., 2015). Furthermore a prostaglandin derivative 
also decreased LOX activity in amniotic tissue leading to decreased cross-linking 
stabilization through the breakdown of exposed non-crosslinked structures that often 
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results in preterm labor (Liu et al., 2016). With much of the current research disregarding 
sex differences, fully understanding the effects of sex specific hormones may lead to a 
more in-depth understanding of enzyme responses beyond LOX. 
Cuproproteins 
Although Cp and LOX have important roles in the body, there are other 
cuproproteins into which Cu can be incorporated. The Cu dependent enzyme Cu Zn 
superoxide dismutase (Cu Zn SOD) damages free radicals produced through oxidative 
metabolism (Keller et al., 1991). With a dimer structure, each subunit contains one of the 
key components; either Cu or Zn (Keller et al., 1991). The absence of the Cu molecule 
renders the enzyme catalytically inactive, while Zn provides only a structural role (Tainer 
et al., 1983; Kim et al., 2008). Previously, it was thought that the Cu chaperone CCS was 
the sole provider of Cu to Cu Zn SOD (Casareno et al., 1998). However CCS knockout 
mice still exhibit some Cu Zn SOD activity (Wong et al., 2000). This activity reveals that 
a secondary Cu chaperone must exist for the delivery of Cu to the SOD enzyme (Wong et 
al., 2000).  Not all organisms rely on CCS to deliver Cu to the SOD enzyme, the 
nematode Caenorhabditis elegans has an alternative mechanism (Jensen and Culotta, 
2005). Through the expression of this nematode enzyme in S. cerevisiae Atx1, Cox17, 
and metallothionein were ruled out leaving GSH as the secondary Cu chaperone (Jensen 
and Culotta, 2005). A depletion of GSH in yeast cells void of CCS resulted in a loss of 
Cu Zn SOD activity that was restored through GSH supplementation (Jensen and Culotta, 
2005). Although both mechanisms are functional for Cu transport it appears that CCS is 
still the primary Cu chaperone as Cu Zn SOD activation does not depend on GSH when 
CCS is present in normal conditions (Jensen and Culotta, 2005). These findings were 
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further investigated in a mouse model in which CCS was absent. As previously seen in 
yeast cells, once depleted of GSH, these CCS knockout mice were void of Cu Zn SOD 
activity (Carroll et al., 2006). This discovery expands our understanding of Cu trafficking 
beyond the three previously known Cu chaperones. 
As an antioxidant Cu Zn SOD has a notable impact on the viability of cells. The 
use of Cu Zn SOD knockout mice revealed that the disfunction of Cu Zn SOD leads to a 
shorter lifespan (Elchuri et al., 2005).  Tumors began to form on the livers of knockout 
mice as young as 20 months old; upon further examination of the livers, signs of 
oxidative damage were seen in the cytoplasm as well as the nucleus and mitochondria to 
a lesser extent (Elchuri et al., 2005). To represent the muscle wasting disorder, 
sarcopenia, Cu Zn SOD knockout mice with increased oxidative stress were utilized (Shi 
et al., 2014). These mice exhibited minimal growth and strength in their hind limbs in 
comparison to wild-type counterparts (Shi et al., 2014). Assessment of the nervous 
system showed that nerve stimulation in the hind limb muscle was dampened in these 
knockout mice due to apparent reactive oxygen species damage to the muscle from the 
lack of Cu Zn SOD sequestration (Shi et al., 2014). These studies among others show that 
the presence of active Cu Zn SOD provides a multitude of benefits to an organism, as the 
dysfunction of the enzyme leads to disarray in the cell from the accumulation of 
unregulated reactive oxygen species. 
Beyond Cu Zn SOD, tyrosinase is also a Cu dependent enzyme. This reliance on 
Cu was tested in mouse melanoma tissue devoid of Cu by cyanide exposure (Lerner et 
al., 1950). Tyrosinase activity in these cells was nearly depleted until the supplementation 
of Cu to the tissue resulted in near 90 percent return of tyrosinase activity in these 
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melanoma cells (Lerner et al., 1950). This apparent need for Cu is rooted in the two Cu 
binding sites that reside within the catalytic site of enzyme (Oetting, 2000; Ismaya et al., 
2011). The corresponding Cu atoms are secured through six histidine residues (Oetting, 
2000). Provided Cu is present at the catalytic site, tyrosinase is responsible for the rate 
limiting step of melanin production (Cooksey et al., 1997). Tyrosinase does not convert 
tyrosine directly to melanin, but rather produces a quinone product, DOPA quinone, that 
is further converted to melanin (Cooksey et al., 1997; Matoba et al., 2006; Ismaya et al., 
2011).  
Mutations in a multitude of possible genes can result in the absence of melanin in 
the skin, hair, and eyes of those affected by albinism due to the lack of tyrosinase activity 
(Montoliu et al., 2014). The early understanding of this condition believed tyrosinase was 
not present in the cell due to observing untouched radio labeled carbon tyrosine 
molecules in both albino skin and hair samples (Fitzpatrick and Kuikita, 1956). Further 
work by Kugelman and Van Scott with hair bulb samples from mutation free and albino 
animal and human subjects indicated that tyrosinase activity can occur in albino hair 
follicles free of inhibitory agents (Kugelman and Van Scott, 1961). These results 
contradict Fitzpatrick and Kuikita’s work, although natural inhibitory factors of 
tyrosinase are found in the skin and may cause partial inactivation of the enzyme leading 
to the varied results of these studies (Kugelman and Van Scott, 1961). The variety of 
genes now associated with albinism may also help to link these findings together, as not 
all mutations elicit the same response (Montoliu et al., 2014). In addition to its 
relationship with albinism, Parkinson’s disease (PD) has also been associated with 
tyrosinase (Hasegawa and Takafumi, 2010). To determine the impact of tyrosinase in 
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neural cells, tyrosinase was overexpressed leading to increased dopamine and reactive 
oxygen species (Hasegawa and Takafumi, 2010). This dopamine acts as a substrate for 
tyrosinase to subsequently produce neuromelanin in the substantia nigra (Hasegawa and 
Takafumi, 2010). The dopaminergic neurons of the substantia nigra are of concern in PD, 
due to the common movement problems associated with the disease occurring with the 
loss of these cells (Greggio et al., 2005). Furthermore, the depigmentation of the 
substantia nigra region is a key attribute of PD, indicating the importance of tyrosinase in 
maintaining neuromelanin (Hasegawa et al., 2008).  An over-abundance of dopamine in 
the cell can result in cytotoxicity; the conversion of dopamine to the more stable 
neuromelanin in part is a protective mechanism against cellular damage if tyrosinase was 
markedly active (Hasegawa and Takafumi, 2010). Overall the role of tyrosinase goes 
beyond simple pigmentation with its function in neuromelanin formation within the 
substantia nigra to aid in maintaining a homeostatic environment within neural cells.  
Copper status and dietary antagonists 
Understanding the role of Cu in the body depends on the ability to evaluate the Cu 
status of the animal. In ruminant animals the liver is widely accepted as the main site of Cu 
accumulation in the body (Kincaid, 2000). The Cu status of an animal can also be obtained 
by analyzing the Cu or Cp content of the plasma. Plasma parameters have proven to be less 
accurate than liver stores because plasma Cu is known to remain constant (Claypool et al., 
1975). As liver stores supply the plasma with Cu, the liver must be depleted before changes 
in plasma Cu are observed (Naylor and Ralston, 1991). An analysis between liver and 
plasma Cu concentrations showed that a drop in plasma Cu was only expected when the 
liver Cu concentration dropped to approximately 40 mg/kg DM or lesser (Claypool et al., 
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1975). Other studies have indicated that plasma Cu is unaffected until liver Cu 
concentrations reach below 20 or 30 mg/kg DM (Mills, 1987). These ranges in liver Cu 
suggest that in some situations the beginning state of Cu deficiency may differ. These 
variations may be dependent upon either Cu source, animal breed, or the presence of an 
antagonist. Similarly, ceruloplasmin can be measured in the plasma as an indicator of Cu 
status, but measurements are variable outside of severe deficiency (Milne, 1998). 
Inconsistency in Cp measurements as a status indicator are a result of Cp functioning as an 
acute phase protein which may indicate unrealistically high Cu status in comparison to 
liver Cu stores during an immune response deeming the sole use of this status indicator 
unreliable (Denko, 1979). A combination of all three Cu status indicators can lead to well-
rounded observations on the Cu status of a ruminant animal. 
 Although measurements of status can be taken, various factors as alluded to earlier 
can influence the uptake or status of an animal. Within cattle, breed has been discovered to 
impact Cu homeostatic mechanisms as Simmental cattle excreted twice as much biliary Cu 
as Angus (Gooneratnet et al., 1994). Additionally, duodenal Cu transporter Ctr1 mRNA 
was decreased and Atp7A mRNA tended to be less in Simmental cows in comparison to 
Angus (Fry et al., 2013). Interestingly, the liver and plasma Cu concentrations between 
these breeds were not different even though Cu transporters were not as apparent in the 
Simmental cows (Fry et al., 2013). The maintained Cu status of Simmental cattle in 
comparison to the Angus breed suggests that there are breed differences in the efficiency 
at which Cu can be absorbed or maintained in the body. Further biological differences may 
impact Cu homeostasis and status but are unknown at this time. Beyond breed differences, 
the dietary allowance of Cu can also impact the status of the animal. Cattle fed adequate 
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dietary Cu, 10 mg Cu/kg DM, have greater liver Cu concentrations in comparison to cattle 
receiving a Cu deficient diet indicating that liver Cu status directly reflects dietary Cu 
content when significant antagonists are not present (Mills, 1987; Dias et al., 2013; Fry et 
al., 2013; NASEM, 2016). Recognizing the potential for breaches in Cu homeostasis may 
be as simple as testing the content of Cu and potent Cu antagonists in the diet to better 
understand what the status of the animal may resemble.  
However, the sole reliance on dietary Cu content as a preliminary status indicator 
may not be sufficient due to dietary interactions. The supplementation of Cu to meet the 
physiological needs of beef cattle during all stages of production is recommended at 10 mg 
Cu/kg DM in the diet (NASEM, 2016). Although this concentration of dietary Cu is 
recognized to maintain growth and prevent symptoms of deficiency, other factors must be 
considered for overall supplementation strategies. The effectiveness of 10 mg Cu/kg DM 
at preventing deficiency symptoms is impacted by the concentration of additional minerals 
in the diet. A connection between Cu and molybdenum (Mo) was demonstrated in cases of 
Cu pine in calves grazing in the United Kingdom. By supplementing Cu sulfate, symptoms 
of un-thriftiness and depigmentation were alleviated from the calves which appeared to 
suffer from Cu deficiency likely caused by high Mo in the grass (Jamieson and Allcroft, 
1949). This indication of a relationship between Cu and Mo was also seen in grazing sheep 
in Australia in which small quantities of Mo resulted in decreased Cu accumulation in the 
liver (Dick and Bull, 1945). The supplementation of 5 mg Mo/kg DM was shown to 
decrease plasma Cu in cattle not supplemented Cu by day 28 of the trial (Ward and Spears, 
1997). Upon analysis of feedstuffs, a dietary Mo concentration in excess of 1-3 mg Mo/kg 
DM is considered to have an antagonistic role, while maintaining a Cu to Mo ratio above 
51 
 
4.5:1 can prevent adverse effects of Mo on Cu utilization (Mortimer et al., 1999). However, 
Mo (molybdate) has little affinity for Cu ions on its own (Alvarez et al., 2010). The addition 
of S to the diet can further exacerbate Cu deficiency resulting in the formation of 
thiomolybdates which are insoluble complexes that render Cu unavailable (Allen and 
Gawthornet, 1987; Arthington, 2003). These thiomolybdates are formed through the 
reaction of molybdate with sulfide in the rumen as proven through the tracking of labeled 
Mo contributions and are primarily in the tri- or tetra-thiomolybdate form when found in 
ruminal digesta (Price et al., 1987). By feeding a combination of 2 mg/kg DM Mo and 
0.3% S in the diet of steers with no supplemental Cu for approximately 90 days liver Cu 
concentrations can be decreased to nearly 90 percent of initial values, proving the potency 
of this antagonism (Hartman et al., 2018). These thiomolybdates are responsible for an 
increase in biliary excretion of Cu from liver stores, a reduction in available circulating Cu 
due to the induction of strong bonds with the carrier albumin, as well as the removal of Cu 
from metalloenzymes (Suttle, 1991).  
In addition to the effects of S and Mo, Zn has been shown to hinder Cu absorption 
and decrease liver Cu concentrations when fed above 100 mg/kg in the diet (Naylor and 
Ralston, 1991). The national recommendation for Zn is 30 mg Zn/kg DM although greater 
concentrations of Zn are fed throughout the industry averaging 109 mg Zn/kg DM 
(NASEM, 2016; Samuelson et al., 2016). Utilizing rats, the association between dietary Zn 
and Cu absorption was explored. The supplementation of excess Zn resulted in depressed 
Cu absorption, when both Zn (1 mg) and Cu (1 μg) were supplemented directly to the 
intestinal segment being measured (Van Campen, 1967). By noting impaired Cu 
absorption, the liver as a point of Zn interference was ruled out (Van Campen, 1967). 
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Further studies utilized fractionated mucosal cells to determine that Cu and Zn were most 
likely binding to the protein metallothionein (Fischer et al., 1981). In addition, with greater 
Zn supplementation, the amount of Cu bound to metallothionein increased, leading to 
greater Cu retention in the mucosal cells (Fischer et al., 1981). The trend in supplementing 
Zn beyond national recommendations may impact Cu absorption. However, a theoretical 
increase in Cu supplementation could offset absorption problems associated with high 
dietary Zn, but the ratio at which these minerals should be included is not well understood. 
Performance attributes from copper supplementation 
As the previous sections have eluded to, Cu plays an essential role in cattle 
growth as a component of various enzymes. Although measuring these specific enzymes 
may demonstrate the importance of Cu, further performance driven results often express 
the holistic significance of the mineral to a broader audience. Through the 
supplementation of varying concentrations of dietary Cu some performance differences 
have been observed. A comparison of Cu sulfate and Cu lysine at 5 mg Cu/kg DM in a 
6.2 mg Cu/kg DM basal diet led to improved gain in Cu sulfate fed steers in comparison 
to both Cu lysine and control steers during the 21 day receiving period (Ward et al., 
1993). However, during the 98 day finishing study performance was unaffected by 
dietary treatment (Ward et al., 1993). Additionally, when steers were injected with 90 mg 
Cu as glycinate prior to weaning and supplemented 5 mg Cu/kg DM in a 2.9 mg Cu/kg 
DM basal diet throughout the growing and finishing trial Cu supplementation resulted in 
greater ADG and improved feed efficiency during the finishing period (Ward and Spears, 
1997). In contrast, Cu supplementation at 20 or 40 mg Cu/kg DM from Cu sulfate or 20 
mg Cu/kg DM from Cu citrate, Cu proteinate, or tribasic Cu chloride (basal diet, 4.9 mg 
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Cu/kg DM) depressed ADG, feed intake and feed efficiency during the finishing period 
(Engle and Spears, 2000a). However, these differences in performance due to Cu 
supplementation are not consistent with further research. The supplementation of Cu at 5, 
10, 20, or 40 mg Cu/kg DM from Cu sulfate or 5 mg Cu/kg DM from Cu lysine in basal 
diets containing between 4.9 and 9.8 mg Cu/kg DM resulted in no differences in ADG, 
DMI, or feed efficiency (Ward et al., 1993; Engle and Spears, 2000b; Engle and Spears, 
2001). It appears that cattle with maintained adequate Cu status (plasma >0.5 mg/L, liver 
> 40 mg Cu/kg DM) do not benefit from further Cu supplementation in regards to growth 
(Ward et al., 1993; Kincaid, 2000). Further, performance may have been positively 
impacted if cattle were Cu deficient prior to the start of Cu supplementation. Overall, 
these studies suggest that Cu supplementation alone does not strongly affect cattle 
performance. However, these studies do not factor in the potential importance of Cu with 
the use of growth promoting technologies. Therefore, additional work to determine the 
effects of Cu on performance of cattle utilizing growth promoting technologies is 
warranted.  
Beyond live animal performance, the supplementation of Cu has been shown to 
have variable effects on carcass characteristics. Cattle supplemented with Cu had leaner 
carcasses with decreased back fat thickness in comparison to cattle on a control diet 
(Ward and Spears, 1997). In steers supplemented with either 10 or 20 mg Cu/kg DM 
from Cu sulfate or Availa Cu (amino acid-bound Cu) back fat was depressed in a 
concentration dependent manner in which cattle supplemented with 20 mg Cu/kg DM 
regardless of source had decreased back fat measurements in comparison to steers 
supplemented with 10 mg Cu/kg DM, with control steers having the greatest back fat 
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measurements (Johnson and Engle, 2003). The effect of dietary Cu on back fat was also 
observed when feeding either 10 or 20 mg/kg DM of Cu from Cu sulfate indicating that 
Cu source is not responsible for these differences (Engle and Spears, 2000b). Further, 
back fat was decreased in steers receiving either 20 or 40 mg Cu/kg DM from either Cu 
sulfate, Cu citrate, Cu proteinate, or tribasic Cu chloride in comparison to control steers 
receiving a basal diet with 10.2 mg Cu/kg DM (Engle et al., 2000).  
In some cases, marbling scores tend to be lesser with Cu supplementation. Steers 
supplemented with 20 mg Cu/kg DM as Availa Cu had lower marbling scores than cattle 
supplemented with 10 mg Cu/kg DM from the same Cu source (Johnson and Engle, 
2003). However, more commonly it has been reported that Cu supplementation does not 
impact marbling scores in either a negative or positive fashion (Engle et al., 2000; Engle 
and Spears, 2000b; Engle and Spears, 2001). In addition, KPH has been shown to 
increase in steers supplemented with 20 mg Cu/kg DM from Availa Cu, having greater 
percent KPH in comparison to control cattle and those supplemented either 10 or 20 mg 
Cu/kg DM as Cu sulfate (Johnson and Engle, 2003). Although this difference in KPH is 
not always noted, as cattle supplemented up to 40 mg Cu/kg DM from multiple sources 
did not differ in KPH (Engle et al., 2000; Engle and Spears, 2000b; Engle and Spears, 
2001). These observances of fat deposition lead to the conclusion that Cu 
supplementation can depress back fat formation and may have an impact on fat 
deposition considering varied effects in marbling scores and KPH, but these differences 
may be cattle dependent and more work is needed to fully understand the role of Cu in fat 
deposition.  
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Understanding the effects of Cu supplementation on these fat deposition 
parameters may be further understood through the role of previously discussed PDE. As a 
regulator of intracellular cAMP, PDE influences the signaling of lipolysis through 
hormone sensitive lipase (Shakur et al., 2001). Hormone sensitive lipase initiates 
lipolysis, the breakdown of triacylglycerol into glycerol and non-esterified fatty acids, 
through PKA mediation (Yeaman, 1990; Krishnamurthy et al., 2014). Further, Cu has 
been detected to bind to PDE, thereby inhibiting its ability to degrade cAMP 
(Krishnamoorthy et al., 2016). Although these effects of Cu were first detected in vitro 
and only confirmed in mice models, it appears that the decrease in back fat measurements 
of Cu supplemented cattle observed here may be a result of lipolysis regulation through a 
Cu dependent mechanism such as Cu inhibited PDE.  
Additionally, the supplementation of these Cu sources at 20 or 40 mg/kg DM 
resulted in decreased HCW in comparison to control steers (Engle et al., 2000). In 
contrast supplementation of Availa Cu at 10 or 20 mg Cu/kg DM resulted in greater 
HCW than controls (basal diet, 6.1 mg Cu/kg DM) with cattle receiving 20 mg Cu/kg 
DM from Availa Cu having greater HCW than steers from the 10 mg Cu/kg DM from 
Availa Cu treatment (Johnson and Engle, 2003). Further, these opposing HCW results are 
contradicted by several studies that have noted no effect on HCW from Cu 
supplementation when fed at 10, 20, or 40 mg Cu/kg DM as Cu sulfate (Engle and 
Spears, 2000b; Engle and Spears, 2001).  
Cattle supplemented with Cu have had varied REA and DP responses and these 
parameters seem to commonly be unaffected by Cu supplementation (Engle et al., 2000; 
Engle and Spears, 2000b; Engle and Spears, 2001). However, the supplementation of 
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Availa Cu at 10 mg Cu/kg DM resulted in greater REA and DP in comparison to the 
same concentration of Cu sulfate (Johnson and Engle, 2003). Further, DP was improved 
to a greater extent when supplemented with 20 mg Cu/kg DM as Availa Cu in 
comparison to the lesser concentration as well as 20 mg Cu/kg DM through Cu sulfate 
(Johnson and Engle, 2003). Overall, these results indicate that Cu supplementation can 
improve the leanness of the carcass through decreased back fat measurements in a 
concentration dependent manner (Engle et al., 2000; Engle and Spears, 2000b; Johnson 
and Engle, 2003). Further, carcass characteristics discussed here have shown varied 
results and indicate that study specific parameters and environmental factors may have 
influenced these findings. Therefore, additional studies are needed to better understand 
the benefits of Cu supplementation on carcass characteristics, particularly in modern 
feedlot cattle utilizing cattle with high growth potential and growth promoting 
technologies.  
Copper Interactions with Growth Promoting Technologies 
As eluded to previously, BA, hormonal implants and Cu supplementation can 
impact either performance or carcass characteristics of cattle when examined on their 
own. Work directed at the possible interactions between bodily requirements for Cu and 
growth promoting technologies has been scant. It appears that Cu may be linked to cAMP 
regulation though PDE (Krishnamoorthy et al., 2016). In isoproterenol stimulated 
adipocytes Cu supplementation led to greater cAMP concentrations confirmed through 
increased phosphorylated hormone sensitive lipase and perilipin detected in Western 
blots of Cu treated cells (Krishnamoorthy et al., 2016). Further, this increase in cAMP is 
a result of PDE inhibition through an interaction with Cu (Krishnamoorthy et al., 2016). 
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The regulation of PDE by Cu appears to be a reversible bond seen specifically in the 
variant PDE3B in this study (Krishnamoorthy et al., 2016). As PDE3B contributes to a 
large proportion of adipocyte PDE activity this regulation by Cu could have a large 
impact on lipolytic activity (Beavo, 1995). The ability to inhibit PDE activity during a 
BA response results in greater production of secondary messenger cAMP and therefore 
greater lipolytic rates that would allow for the leaner carcasses expected in cattle fed a 
BA. To better understand the details of this Cu and PDE relationship, more research is 
warranted both in vitro and in vivo.  
In addition to the connection between Cu and the BA pathway the role of Cu in 
growth is evident as the Cu dependent enzyme LOX catalyzes the crosslinking of 
collagen and elastin within the ECM of cells (Zhang et al., 2015). This crosslinking leads 
to the structural integrity of the cell thus supporting growth through both structural and 
functional proteins in the ECM that are involved in tissue development (Gentili and 
Cancedda, 2009). As described previously LOX activity has been shown to decrease in 
ligament tissue when treated with E2 (Lee et al., 2015). This interplay between E2 
treatment and LOX activity provides evidence for a hormonal effect on growth in relation 
to Cu status. Further, E2 appears to impact circulating Cp (Sunderman et al., 1971). Daily 
injections of E2 in mice resulted in elevated serum Cp that began to plateau after 28 days 
of E2 treatment (Sunderman et al., 1971). This increase in circulating Cp suggests that the 
Cu requirement of tissues treated with E2 is greater as Cp delivers Cu to target tissues. It 
is unclear why E2 would decrease LOX activity while increasing circulating Cp. With the 
understanding that hormonal implants enhance growth, one would expect E2 treatments to 
enhance LOX activity as increased growth would presumably require a greater need for 
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LOX activity to provide cellular structure. Further, the increase in circulating Cp suggests 
a greater need for Cu in tissues. As LOX activity is decreased this need for Cu must be 
used by another source. It is unclear what other enzyme or mechanism is utilizing this 
upregulated Cu (from Cp) when tissue is treated with E2.  
Beyond the basic interactions between Cu and growth promoting technologies it 
appears that minerals can impact the performance of cattle receiving growth promoting 
technologies such as implants and beta agonists. Limited research in cattle on potential 
relationships between growth promoting technologies and minerals is available. 
Therefore, these results do not provide conclusive evidence and represent the need for 
further research in this area. The supplementation of Zn has been shown to accommodate 
the growth response of implanted cattle. The ADG of steers implanted with 20 mg 
estradiol benzoate and 200 mg progesterone (Synovex-S) was improved by 7.6 and 
17.4% in control steers fed a basal diet containing 84 mg Zn/kg DM and steers fed 200 
mg Zn/kg DM from  Zn sulfate, respectively, in comparison to nonimplanted steers 
(Huerta et al., 2002). Implanted heifers of the control and Zn sulfate treatments 
experienced similar increases in ADG over nonimplanted heifers, 11 and 17% 
improvements, respectively (Huerta et al., 2002). Further the supplementation of 200 mg 
Zn/kg DM of Zn-methionine to implanted steers resulted in no differences in gain when 
compared to nonimplanted steers (Huerta et al., 2002). In contrast, nonimplanted heifers 
fed the Zn-methionine treatment had 26% greater ADG than implanted heifers of the 
same treatment (Huerta et al., 2002). An additional study looked at industry versus 
national recommendations of trace minerals on the performance of cattle receiving a high 
potency implant program (Niedermayer et al., 2018). This study indicated that during the 
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first 56 days on a medium potency implant (80 mg TBA and 16 mg E2) implanted steers 
fed the national and industry mineral recommendations had improved ADG over their 
non-trace mineral supplemented counterparts (Niedermayer et al., 2018). However, the 
following terminal implant (200 mg TBA and 20 mg E2) revealed no interactions with 
trace minerals and the implant for the remainder of the study (Niedermayer et al., 2018). 
This improved growth at the beginning of the trial suggests that proper mineral nutrition 
may be most critical during this time of high growth as previously discussed with the 
decline of satellite cell proliferation with age. In addition, minerals have been observed to 
interact with BA induced growth. Supplementing RAC treated steers (300 mg·day-1·steer-
1) with 60 mg Zn/kg DM from a Zn amino acid complex plus 60 mg Zn/kg DM from Zn 
sulfate resulted in a 1.3% increase in HCW in comparison to RAC treated steers not 
receiving supplemental Zn amino acid complex (Genther-Schroeder et al., 2016). 
The augmentation of performance in cattle utilizing growth promoting 
technologies with mineral supplementation strategies is a new area of research. These 
performance results suggest that the mineral requirements of cattle utilizing growth 
promoting technologies are increased to allow for a more optimal growth response as 
increased supplementation of minerals such as Zn have been shown to improve 
performance. The limited data within this area of study also indicate that more work is 
needed to fully understand the ideal supplementation of individual minerals to achieve 
optimal growth with the use of growth promoting technologies.  
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CHAPTER 3. EFFECTS OF LIVER COPPER CONCENTRATION AND 
DIETARY COPPER CONCENTRATION ON RACTOPAMINE 
HYDROCHLORIDE PERFORMANCE AND CARCASS CHARACTERISTICS 
OF FINISHING STEERS 
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Abstract 
To determine the effect of copper (Cu) status on beta agonist (BA) induced 
growth, 96 Angus-cross steers (470 ± 35 kg) were assigned to a 3 × 2 factorial. Factors 
included Cu-supplementation (mg Cu/kg DM) at: 0 (LOW), 10 (MED), or 20 (HIGH) 
from Availa-Cu (Zinpro; Eden Prairie, MN) and the BA ractopamine hydrochloride from 
Optaflexx (Elanco, Greenfield, IN) at 0 (NoRAC) or 300 mg·steer-1·d-1 (RAC) for the 
final 28-d of the 88-d trial. Steers were blocked by liver Cu, developed in a prior trial to 
distinct statuses of 6, 14, and 53 mg/kg DM (SEM 2.0) for LOW, MED, and HIGH, 
respectively, stratified by BW to pens of 6, and fed via GrowSafe bunks. Steer was the 
experimental unit (n = 12 or 18 per treatment) and initial BW from the prior trial was 
used as a covariate in performance analyses. Consecutive day BW were collected on d -1, 
0, 60, 61, 87, and 88 with intermediate BW on d 28, 40, and 75. Blood samples were 
collected on d -1, 60, 66, 67, 75, and 87 and liver biopsies collected on d -23, 53, and 
during harvest.  Contrast statements were constructed to determine linear and quadratic 
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effects of Cu status within BA treatment. Day 53 liver Cu quadratically increased to 14, 
166, and 266 mg/kg DM (P ≤ 0.0001; SEM 8.7). Pre-BA growth was not affected by Cu-
supplementation (P ≥ 0.51). Linear and quadratic effects of Cu within BA treatment were 
tested in BA period. Copper-supplementation of RAC steers quadratically increased 
average daily gain (P = 0.002) and tended to increase dry matter intake, feed efficiency, 
and ribeye area (P ≤ 0.1) driven by greatest performance in MED steers. No other carcass 
characteristics were affected by Cu-supplementation regardless of BA treatment (P ≥ 
0.16). Regardless of Cu, feeding BA tended to increase hot carcass weight (P = 0.08; 412 
and 404 kg, for RAC and NoRAC respectively, SEM 3.5). Harvest liver Cu 
concentrations quadratically increased with dietary Cu-supplementation regardless of BA 
treatment (P < 0.0001). Serum non-esterified fatty acids tended to exhibit a BA × Day 
interaction (P = 0.08) in which NEFA decreased after 14 days of BA treatment for both 
RAC and NoRAC steer, however RAC steers had lesser serum NEFA concentrations. 
Feed efficiency during BA period linearly decreased as Cu-supplementation increased in 
NoRAC steers (P = 0.04). Increasing dietary Cu effectively increased Cu status, however 
RAC steers receiving 10 mg Cu/kg DM performed best during the BA period. These data 
suggest beta-agonist response is influenced by Cu status of steers. 
Key words: beef steers, copper, ractopamine hydrochloride 
 
Introduction 
Improved animal performance through the utilization of beta agonists (BA) is 
attributed to the repartitioning of energy from fat deposition to muscle accretion 
(Mersmann, 1998). Nearly 85% of cattle represented in a survey of consulting 
nutritionists and feedlot managers are fed a BA (Birch, 2015; Samuelson et al., 2016). 
83 
 
The use of BA is associated with increased live body weight (BW), hot carcass weight 
(HCW), and ribeye area (REA); as well as improved feed efficiency while decreasing 
marbling score (Lean et al., 2014). These characteristics are a result of the BA pathway in 
which intracellular messenger cyclic AMP (cAMP) mediates the activation of hormone 
sensitive lipase for the initiation of lipolysis (Mersmann, 1998). Lipolysis is impeded by 
phosphodiesterases (PDE) regulating BA activity through cAMP degradation (Conti et 
al., 2003). To accommodate BA induced growth, cattle may require additional nutritional 
resources such as copper (Cu). Growth is affected through Cu-dependent lysyl oxidase 
which is responsible for the crosslinking of collagen within the extracellular matrix and 
thus structural integrity of cells (Rucker et al., 1998). Additionally, recent evidence 
suggests Cu may affect lipolysis as tissue Cu concentrations and lipolytic activity of 
adipocytes in mice concurrently decreased (Krishnamoorthy et al., 2016). Furthermore, 
cellular models reveal that reversible binding of Cu to PDE may dampen the activity of 
this known BA inhibitor (Krishnamoorthy et al., 2016). Taken together, these studies 
suggest that Cu status may positively impact the performance of cattle fed BA through 
restricted PDE degradation of the cAMP signal. The objective of this study was to 
determine the effects of initial Cu status on performance and carcass characteristics of 
steers consuming or not consuming a BA. It was hypothesized that as Cu status improved 
the BA response would be consequently enhanced. 
Materials and Methods 
All procedures and protocol in this study were approved by the Iowa State 
University Institutional Animal Care and Use Committee (log number 5-17-8522-B). 
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Animals and experimental design 
 Ninety-six single source Angus-cross steers (470 ± 35 kg) were utilized in a 3 × 2 
factorial design experiment. These steers were utilized in a previous trial in which three 
distinct Cu statuses were induced through the dietary inclusion of Cu antagonists S and 
Mo. Steers were blocked by initial liver Cu concentration into three dietary treatments to 
maintain liver Cu concentration throughout the trial. Prior to initiation of the study three 
steers were removed for health concerns. Dietary treatments included LOW, MED, and 
HIGH receiving 0, 10, or 20 mg of Cu/ kg DM from Availa-Cu (Zinpro, Eden Prairie, 
Mn), respectively. These treatments represent no supplemental Cu, national 
recommendations and industry consultant reported supplementation for LOW, MED, and 
HIGH treatments, respectively (NASEM, 2016; Samuelson et al., 2016). Within Cu 
treatment steers were stratified by BW and randomly assigned to pens of 6 with 
GrowSafe bunks (GrowSafe Systems Ltd., Airdrie, AB, Canada) and automatic waterers.  
 Consecutive day BW were taken at the beginning the Pre-BA period (d -1 and 0), 
the BA period (d 61 and 62), and at the end of the experiment (d 87 and 88). Cattle were 
implanted with a Component TE-IS (Elanco Animal Health, Greenfield, IN) on day 0 
followed by a Component TE-S (Elanco Animal Health, Greenfield, IN) on day 40. On 
day 62 half of the pens from each dietary Cu treatment were randomly assigned to 
receive ractopamine hydrochloride (Optaflexx; Elanco Animal Health, Greenfield, IN) at 
300 mg·steer-1·day-1. Cattle were shipped to a commercial abattoir (Iowa Premium Beef, 
Tama, IA) on day 88 and were harvested on day 89. Following a 48-hour chill carcass 
data were collected including HCW, REA, BF, KPH, marbling score, and YG. 
Additionally, DP was calculated by dividing the shrunk live final BW by the HCW and 
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multiplying by 100. A 4 % pencil shrink was applied to all BW before ADG and G:F 
were calculated.  
Feed and tissue sampling and analysis 
 Cattle were fed a common dry rolled corn-based diet supplemented with NASEM 
(2016) recommendations for all minerals except Cu (Table 1). During the Pre-BA period 
an error in DM was recognized for modified distillers grains solubles and it was found 
most appropriate to correct upon the start of the BA period. Thus, steers received the Pre-
BA diet from d 0-60, and the BA diet from d 61-87. The diet was delivered at 
approximately 0800 h daily and bunks were managed to allow for ad libitum feed intake. 
Total mixed rations (TMR) were sampled weekly and dried in a forced air oven at 70˚C 
for 48 hours to determine dry matter (DM). Utilizing the weekly DM from TMR samples, 
individual steer DMI was determined from as-fed intakes. Feed efficiency (G:F) was 
calculated for both the Pre-BA and BA periods using total weight gained in that period 
divided by the total amount of feed consumed on a DM basis during that period. Dried 
diet samples were ground through a 2-mm screen (Retsch Zm100 grinder; Glen Mills 
Inc., Clifton, NJ) and samples were composited monthly in accordance with the Pre-BA 
and BA periods. Liver biopsies were conducted on three randomly sampled steers from 
each pen on day -23 and 53 in accordance with the method described by Engle and 
Spears (2000) while final liver samples were collected at harvest. The same three steers 
were utilized for liver samples throughout the experiment. Jugular blood samples were 
collected from all animals on days 0, 60, 66, 67, 75, and 87. Composited TMR samples 
and liver samples were acid digested with trace mineral grade nitric acid (Fisher 
Scientific, Fair Lawn, NJ) as described by Richter et al. (2012). Liver, plasma, and TMR 
86 
 
samples were analyzed for Cu and Zn using inductively coupled plasma optical emission 
spectrometry (Optima 7000 DV, Perkin Elmer, Waltham, MA) as described by (Pogge et 
al., 2014). Further, the S content of TMR samples were calculated from inclusion of 
feedstuffs in the diet. Blood samples were collected in vacutainer tubes with no additives 
for serum, trace mineral grade EDTA, and EDTA for other analysis (Becton Dickenson, 
Rutherford, NJ). Tubes were spun in a centrifuge at 1200 x g for 10 minutes for plasma 
and at 1200 x g for 20 minutes for serum samples. Serum and trace mineral plasma was 
stored at -20˚C prior to analysis. Serum NEFA was analyzed using a commercial kit 
(Wako Pure Chemical Industries Ltd., Chuo-Ku Osaka, Japan). Blood analysis was 
completed with inter-assay and intra-assay CV values less than or equal to 10.  
Statistical analysis 
 Data from the pre-BA period were analyzed as a randomized block design using 
the Mixed procedure of SAS 9.4 (SAS Inst. Inc., Cary, NC). Steer was experimental unit 
(n = 24 for LOW or 36 per MED and HIGH treatment) with a model including the fixed 
effect of Cu. Contrast statements to test for a linear or quadratic effect of Cu treatment 
were utilized for analysis of data during this period. Data from the BA period, d 61-88, 
were analyzed as a 3 × 2 factorial using the Mixed procedure of SAS 9.4 using the fixed 
effects of Cu, BA, and Cu × BA. Contrast statements were formed to test for both linear 
and quadratic effects of Cu treatment within cattle that did not receive BA (L-Cu, Q-Cu) 
and within cattle that did receive BA (L-CuRAC, Q-CuRAC). Analysis of serum NEFA 
data was conducted as repeated measures with day of sampling as the repeated effect. 
The experimental unit was steer, except for liver samples (n = 6 for LOW treatments or 9 
for all other treatments). Initial liver Cu from the prior trial (d -119) was utilized as a 
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covariate in liver Cu analysis. Liver trace mineral data were log transformed to fit a 
normal distribution based on Shapiro-Wilk test for normality. In addition, Cook’s D was 
used to evaluate data for outliers. Data from two steers (one from HIGH and one from 
MED-RAC) were removed from analysis due to poor performance unrelated to treatment. 
Prior to the start of the trial 3 steers were removed due to poor performance or health 
related issues (n = 12 per LOW treatment, 16 for MED-RAC, 17 for MED-NoRAC, 18 
for HIGH-RAC, and 16 for HIGH-NoRAC). Data reported are least square means with 
standard error of the mean. Statistical significance was determined at P ≤ 0.05, and a 
statistical tendency was determined at 0.05 < P ≤ 0.10.    
Results 
Pre-beta agonist period performance and copper status 
Throughout the Pre-BA period, no differences in performance were observed for 
d 0 BW, d 62 BW, DMI, ADG, or feed efficiency (Table 2; P ≥ 0.15). As expected initial 
liver Cu concentrations of steers linearly increased with greater Cu supplementation (P = 
0.01). By the end of the Pre-BA (d 61) period liver Cu concentrations quadratically 
increased with greater concentrations of dietary Cu supplemented (P = 0.01).  
Beta agonist period and overall growth performance    
 Steer BA period and overall growth performance data are shown in Table 3.  
During the BA period DMI tended (P = 0.10) to quadratically increase due to Cu 
supplementation within RAC, with MED steers having greater DMI than their 
counterparts. Moreover, RAC supplemented steers quadratically improved ADG with 
increasing dietary Cu, again driven by MED-fed steers (P = 0.01), resulting in a tendency 
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for a quadratic increase in G:F due to Cu supplementation of RAC treated steers (P = 
0.08). Within NoRAC steers, Cu supplementation did not affect ADG (P = 0.43) and 
linearly decreased G:F (P = 0.04).  Final live BW of steers on d 87, as well as carcass 
adjusted final BW and overall DMI, ADG, and G:F were not affected by Cu 
supplementation within BA treatment (P ≥ 0.19).  
Carcass characteristics 
 Final liver Cu concentrations and steer carcass data are shown in Table 4. 
Following harvest liver Cu concentration of steers was quadratically increased due to 
greater Cu supplementation regardless of BA treatment (P = 0.01). Further, HCW, DP, 
marbling, back fat, KPH, and yield grade were unaffected by Cu supplementation within 
BA strategy (P ≥ 0.31). However, REA of RAC treated steers tended (P = 0.08) to 
quadratically increase with MED steers having the largest REA, while no impact of Cu 
supplementation within NoRAC steers on REA was noted (P ≥ 0.38).  
Blood analysis 
 There was a tendency for NEFA to display a BA × Day interaction (P = 0.08; 
Figure 1) in which NEFA decreased for both NoRAC and RAC steers on day 14 of BA 
supplementation in comparison the beginning and end of BA period (d 61 and 87, 
respectively) although RAC steers had lesser NEFA concentrations throughout trial than 
NoRAC steers.  
Discussion 
 Beta agonists are widely used throughout the feedlot industry because of the gain 
in efficiency and lean muscle accretion this technology provides (Birch, 2015; Samuelson 
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et al., 2016). Beta agonists such as ractopamine hydrochloride or zilpaterol hydrochloride 
improve live final BW and HCW between 8 and 15 kg (Lean et al., 2014). Previous work 
has indicated the supplementation of Zn to cattle receiving a BA improves performance 
suggesting a role for trace minerals in the BA response (Genther-Schroeder et al., 2016a). 
In contrast to Zn, liver stores of Cu are well accepted as status indexes allowing for clear 
evaluation of the effect of status through liver Cu concentrations. Therefore, this study 
was designed to assess the effect of liver Cu concentrations on BA-induced growth and 
carcass characteristics.  
Interestingly, the three Cu treatments at the initiation of the trial represented steers 
that were deficient or within the marginal range of Cu status based on liver Cu 
concentrations (Kincaid, 2000). Although initially deficient, the rapid increase in liver Cu 
concentration by d 53 in MED and HIGH steers may have been enhanced by the 
transition to a high concentrate diet from an 85% corn silage diet. The change in diet 
likely resulted in a drop in ruminal pH, allowing for greater solubility of Cu in the rumen 
(NASEM, 2016). In addition to this ruminal pH shift, steers were previously fed a diet 
with the potent Cu antagonists S and Mo. With the removal of supplemental S and Mo, 
MED and HIGH cattle were able to rapidly improve liver Cu concentrations. The stark 
increases of both MED and HIGH steers in liver Cu concentrations during the 53-day 
period were in contrast to the minimal improvement in liver Cu concentrations of LOW 
steers. The continued improvement in liver Cu concentration of MED and HIGH steers 
and inability of LOW steers to improve deficient liver Cu concentrations through the 
entirety of the trial suggest that 6.0 mg Cu/kg DM analyzed in the common diet was not 
enough to meet bodily requirements for Cu and improve Cu concentration in the liver to 
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an adequate range. Though S was not supplemented in the present study, the inclusion of 
coproducts such as modified distillers grains with solubles resulted in a calculated dietary 
S concentration of 0.33% which was likely sufficiently high to interfere with Cu 
absorption, resulting in the inability of LOW steers to improve liver Cu concentrations to 
the same degree as MED and HIGH steers.  
The three distinct Cu statuses observed in the Cu treatments allow differences in 
performance and carcass characteristics to be attributed to Cu status based on liver Cu 
concentrations. During the BA feeding period ADG, DMI, G:F, and REA were greatest 
in MED-RAC steers while NoRAC steers experienced a numerical increase in DMI and 
subsequently a linear decrease in feed efficiency with increasing Cu supplementation. 
Both MED-RAC (227 mg Cu/kg DM) and HIGH-RAC (324 mg Cu/kg DM) treatments 
regardless of BA treatment had adequate liver Cu concentrations (125-600 mg Cu/kg 
DM) during the BA period (Kincaid, 2000). The clear improvement in performance of 
MED-RAC steers over HIGH-RAC during the BA feeding period may suggest that liver 
Cu concentrations of ~250 mg Cu/kg DM are more favorable than those in excess of 300 
mg Cu/kg DM. These differences in performance indicate liver Cu adequacy and dietary 
supplementation of Cu should be further classified to reflect optimal growth, with or 
without use of growth promoting technologies. Data in the present study imply that the 
NASEM (2016) recommendation for Cu supplementation is beneficial to BA-induced 
growth in comparison to no supplementation or Cu supplementation at current industry 
reported averages. Additional work is needed to refine optimal liver Cu concentrations 
and whether more or less than 10 mg Cu/kg DM is optimal to support BA induced 
growth.  
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The influence of dietary Cu content on growth of steers during the BA period may 
be associated with the physiological role of Cu downstream of BA receptor activation. 
Recent cell culture and rodent research has demonstrated that Cu is positively associated 
with lipolytic activity through the reversible regulation of PDE in adipocytes 
(Krishnamoorthy et al., 2016). Previously, Zn was indicated to also reversibly bind to 
PDE as a regulatory mechanism, and was shown to decrease gene expression of PDE 
(von Bülow et al., 2005). Through both of these studies cAMP was altered due to mineral 
concentrations of media (von Bülow et al., 2005; Krishnamoorthy et al., 2016). Further, 
increasing supplemental Zn in cattle has been shown to linearly increase plasma cAMP, 
suggesting the inhibition of PDE through Zn (Genther-Schroeder et al., 2016a). Increased 
availability of cAMP to activate protein kinase A and subsequently hormone sensitive 
lipase (Beavo et al., 1974; Mersmann, 1998) would support hydrolysis of 
triacylglycerides, increasing release of free fatty acids from adipose tissue to be used as 
energy for the accretion of muscle (Yeaman, 1990). As Cu has been identified as a 
regulator of PDE, the cAMP pool would be expected to be greater with increasing 
supplementation of Cu leading to more lipolysis. However, plasma cAMP concentrations 
were not assessed in the present trial. The improved performance of MED-RAC steers in 
comparison to LOW-RAC and HIGH-RAC steers does not directly follow the linear 
trend that is observed in Zn studies. It is unclear why supplementing 20 mg Cu/kg DM 
was not beneficial to BA performance when 10 mg Cu/kg DM elicited a growth response. 
It is possible that greater concentrations of Cu may have led to faster desensitization of 
the beta-adrenergic receptor, but research to support this claim is lacking.  
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Serum NEFA decreased for both NoRAC and RAC steers on d 66 from d 61 
values but were greater on d 87 than 66. Although NoRAC and RAC steers followed 
similar trends, RAC steers had lesser serum NEFA concentrations than NoRAC steers. 
The decrease in serum NEFA for RAC steers may have been due to released NEFA from 
BA-induced lipolysis being utilized as energy by growing tissues rather than 
accumulating in the serum. However, the difference in serum NEFA for both NoRAC 
and RAC steers between days may have been due to the diet change that occurred at the 
beginning of the BA period. The inhibition of PDE by Cu described earlier should 
support increased lipolysis and thus it was expected that serum NEFA would be greater in 
RAC-fed steers as dietary Cu increased; however, Cu appeared to have no impact on 
serum NEFA. The role of Cu in potentially stimulating lipolysis may be the underlying 
reason why previous Cu studies have seen a decrease in back fat with increasing Cu 
supplementation (Engle et al., 2000a; Engle and Spears, 2000; Engle and Spears, 2001; 
Johnson and Engle, 2003). However, neither Cu or BA impacted back fat measures in the 
present trial. Additionally, the effect of Cu on lipolysis is clouded by the numerical trend 
for marbling to increase with increasing Cu supplementation as inhibition of PDE would 
suggest greater lipolytic rates. However, studies have shown a decrease in back fat in 
steers while not affecting marbling suggesting back fat is more directly targeted by 
lipolysis than intramuscular fat deposits (Engle et al., 2000b; Engle et al., 2000a; Engle 
and Spears, 2000). Indeed, Pothoven et al. (1975) demonstrated that fatty acid synthesis 
and thus lipolytic rate vary among tissues suggesting that back fat and marbling may not 
be affected in a similar manner.  
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In the present trial LOW steers performed well even though liver Cu 
concentrations are quite different from Cu supplemented steers. The comparable growth 
rates of LOW steers to MED and HIGH counterparts may in part have been due to the 
diet shift at the beginning of the BA period. Through the shift to more corn by-products 
in the diet, metabolizable protein in the diet during the BA period provided 47% greater 
metabolizable protein than the steers required. Although adequate, the Pre-BA period 
provided 21% more metabolizable protein than the requirement of the steers based upon 
observed BW, DMI, and ADG for each respective period. It is possible that increasing 
metabolizable protein during the BA period resulted in greater growth rates than may be 
typically expected late in the finishing period for steers. The consistently excellent 
growth observed in LOW steers, despite deficient Cu status as determined by liver Cu 
concentrations, suggests that late stage finishing cattle likely have a lesser Cu 
requirement than is currently recommended (NASEM, 2016). 
  Zinc has been more extensively studied than Cu with the supplementation of 
BA. Increasing supplemental Zn appears to be beneficial during BA supplementation as 
final BW, ADG, and G:F linearly increased (Genther-Schroeder et al., 2016a). Additional 
work led to similar results in which supplementation of Zn led to improved HCW, final 
BW, and carcass adjusted ADG of steers treated with BA (Genther-Schroeder et al., 
2016b). Interestingly, in both of these studies steers not supplemented with BA did not 
exhibit improved performance due to Zn supplementation (Genther-Schroeder et al., 
2016b; Genther-Schroeder et al., 2016a). Unlike the linear performance response elicited 
through Zn supplementation, the response to Cu supplementation appears to have an 
optimal dietary Cu concentration most near NASEM (2016) recommendations, in which 
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more or less dietary Cu may limit BA-induced performance. Additionally, the 
supplementation of trace minerals such as Cu and Zn to cattle not receiving BA appears 
to have little to no response on performance in these studies. In finishing pigs the 
supplementation of Cu or Zn at 125 and 150 mg/kg DM, respectively, led to improved 
feed conversions during BA supplementation in comparison to control pigs; however, 
combining Cu and Zn did not result in an additive effect or improve efficiency from 
control pigs (Feldpausch et al., 2015). Because the metabolism of Cu and Zn are 
interrelated more work is needed to assess the effects of altering one or both of these 
critical trace minerals in the diets of livestock receiving BA.  
Overall, steers receiving BA experience a differential response in performance 
due to increasing supplemental Cu in comparison to steers within the NoRAC treatment. 
This suggests that Cu influences the pathway in which BA elicit a growth response, 
potentially through the inhibition of PDE. Furthermore, these data suggest that NASEM 
(2016) recommendations for Cu are adequate for BA induced growth while greater or 
lesser concentrations of Cu may cause adverse impacts on cattle performance when 
utilizing a BA. To fully understand the mechanism in which Cu influences BA growth 
and distinguish between Cu status and dietary Cu more work is warranted.  
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Table 1. Ingredient and composition analysis of un-supplemented diet in pre-beta 
agonist and beta agonist period 
 Pre-BA Period BA Period 
Ingredient % of diet DM % of diet DM 
     Dry rolled corn 68.9 62.0 
     MDGS1 16.7 25.0 
     Bromegrass hay   8.9   8.0 
     DDGS2   3.33   3.05 
     Limestone   1.7   1.5 
     Salt   0.31   0.31 
     Vitamin & mineral premix3   0.13   0.13 
     Rumensin   0.0135   0.0135 
Analyzed composition, %   
     Crude protein4 12.62 15.31 
     NDF4 20.14 19.35 
     Ether extract4   4.03   4.69 
     Cu, mg/kg DM5   6.0   6.0 
     Zn, mg/kg DM6 64.4 72.0 
Calculated composition, %   
     Sulfur   0.33   0.33 
1Modified distillers grains with solubles. 
2Dried distillers grains with solubles. 
3Premix provided 2,200 IU vitamin A and 25 IU vitamin E/kg diet and NASEM 
(2016) recommendations for Co, Mn, Se, Zn, and I from inorganic sources in 
addition to 0, 10, or 20 mg Cu/kg DM from Availa Cu (Zinpro Corporation, Eden 
Prairie, MN). 
4Analysis were completed by Dairyland Laboratories (Arcadia, WI). 
5Analyzed Cu values represent LOW dietary treatment total, MED and HIGH dietary 
treatments analyzed at 16 and 25 mg Cu/kg DM, respectively. Trace mineral 
treatments included: LOW (no supplemental trace mineral), MED (2016 
recommendation of 10 mg Cu/kg DM), and HIGH (feedlot consultant 
recommendations of 20 mg Cu/kg DM; Samuelson et al. (2016)). Supplementation of 
Cu was delivered as Availa Cu (Zinpro Corporation, Eden Prairie, MN) and all other 
minerals were supplemented at national recommendations utilizing inorganic 
sources. Values analyzed by inductively couples plasma optical emission 
spectrometry (ICP Optima 7000 DV, Perkin Elmer, Waltham, MA). 
6Analyzed Zn values represent LOW dietary treatment for both Pre-BA and BA 
period measured by inductively coupled plasma optical emission spectrometry (ICP 
Optima 7000 DV, Perkin Elmer, Waltham, MA). 
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Table 2. Effect of supplemental copper on copper status and performance during pre-beta agonist period 
 
 Copper4  Contrasts5 
Item1,2,3 Low Med High SEM Lin Quad 
   steers (n)      24      36      36    
   d -23 liver Cu, mg/kg DM        6      14      53       2.0     0.01     0.06 
   d 53 liver Cu, mg/kg DM      14    166    266       8.7     0.01     0.01 
   d 0 BW, kg    466    470    473       5.1     0.33     0.91 
   d 62 BW, kg    579    586    588       6.9     0.32     0.79 
   DMI, kg/d      12.1      12.3      12.6       0.23     0.15     0.78 
   ADG, kg        1.8        1.9        1.9       0.05     0.57     0.72 
   G:F        0.151        0.152        0.148       0.0034     0.61     0.51 
1Pre-BA period encompasses days 0 through 61 of trial. 
2A 4% pencil shrink was applied to all live BW measures including ADG. 
3Performance data were analyzed with prior trial start weight as covariate. 
4Trace mineral treatments included LOW (no supplemental trace mineral), MED (2016 recommendation 
of 10 mg Cu/kg DM), and HIGH (feedlot consultant recommendations of 20 mg Cu/kg DM; Samuelson 
et al. (2016)). Supplementation of Cu was delivered as Availa Cu (Zinpro Corporation, Eden Prairie, 
MN) and all other minerals were supplemented at national recommendations utilizing inorganic sources. 
5Contrasts analyzed data to determine either a linear or quadratic relationship among dietary Cu 
treatments 
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Table 3. Performance of steers fed varying copper concentrations and ractopamine hydrochloride during beta agonist period 
 
Beta agonist1 NoRAC RAC  Contrasts2 
Copper3 Low Med High Low Med High SEM A B C D 
Item4            
   steers (n)   12   18   18   12   18   18      
BA period5            
   d 87 BW, kg 640 645 642 645 661 662 10.2 0.34 0.62 0.28 0.80 
   DMI, kg/d   11.7   12.1   12.5   11.8   12.7   12.2   0.38 0.12 0.97 0.45 0.10 
   ADG, kg     2.39     2.24     2.28     2.33     2.75     2.47   0.1 0.43 0.39 0.27 0.01 
   G:F     0.206     0.186     0.183     0.198     0.216     0.205   0.0079 0.04 0.34 0.51 0.08 
Carcass adjusted6,7            
   d 88 BW, kg 643 643 641 647 661 661 10.7 0.92 0.92 0.31 0.58 
   Overall DMI, kg/d   11.9   12.1   12.4   12.0   12.5   12.4   0.33 0.19 0.96 0.32 0.38 
   Overall ADG, kg     2.0     2.0     2.0     2.1     2.1     2.1   0.07 0.87 0.78 0.89 0.56 
   Overall G:F     0.164     0.164     0.159     0.171     0.168     0.164   0.0005 0.46 0.65 0.28 0.90 
1Ractopamine hydrochloride (RAC) treatment was initiated 28 days prior to harvest at an inclusion of 300 mg·steer-1·day-1. 
2Contrasts utilized to analyze this period of data test linear and quadratic relationships in Cu supplementation when RAC was not 
supplemented (A and B, respectively) and when RAC was supplemented (C and D, respectively). 
3Dietary Cu treatments consisted of LOW (no supplemental trace mineral), MED (2016 recommendation of 10 mg Cu/kg DM), and 
HIGH (feedlot consultant recommendations of 20 mg Cu/kg DM; Samuelson et al. (2016)). Supplementation of Cu was delivered 
as Availa Cu (Zinpro Corporation, Eden Prairie, MN) and all other minerals were supplemented at national recommendations 
utilizing inorganic sources 
4A 4% pencil shrink was applied to all live BW measures including G:F calculations. 
5Evaluation of performance data during beta agonist period, d 61-88 
  
1
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6Carcass adjusted overall performance utilized final BW calculated by dividing HCW by average dressing percent (62.8%). 
7Performance data analyzed with prior trial starting weight as covariate. 
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Table 4. The effect of copper supplementation and ractopamine hydrochloride treatment on carcass characteristics of beef 
finishing steers 
Beta agonist1 NoRAC RAC  Contrasts2 
Copper3  Low Med High Low Med High SEM A B C D 
Item            
   steers (n)    12    18    18    12    18    18        
Carcass characteristics4            
   d 89 liver Cu, mg/kg DM    18  232  289    33  227  324   18.6  0.01  0.01  0.01  0.01 
   HCW, kg5  404  404  403  406  415  415     6.7  0.92  0.91  0.31  0.58 
   Dressing percent, %    63.1    62.7    62.8    63.0    62.8    62.7     0.34  0.53  0.51  0.59  0.79 
   Ribeye area, cm2    93.4    91.1    90.9    92.6    98.1    95.5     2.13  0.38  0.65  0.29  0.08 
   Marbling6  427  463  472  422  458  461   23.4  0.16  0.59  0.21  0.52 
   Back fat, cm      1.46      1.46      1.37      1.52      1.45      1.41     0.136  0.61  0.71  0.53  0.87 
   KPH, %7      2.3      2.6      2.5      2.4      2.4      2.5     0.16  0.48  0.23  0.64  0.87 
   Yield grade      3.15      3.33      3.21      3.30      3.02      3.14     0.194  0.82  0.46  0.52  0.36 
 
1Ractopamine hydrochloride (RAC) treatment was initiated 28 days prior to harvest at an inclusion of 300 mg·steer-1·day-1. 
2Contrasts for linear and quadratic relationships in dietary Cu treatment within cattle not receiving ractopamine hydrochloride 
(A and B, respectively) and cattle receiving ractopamine hydrochloride (C and D, respectively) were utilized for analysis. 
3Dietary Cu treatments consisted of LOW (no supplemental trace mineral), MED (2016 recommendation of 10 mg Cu/kg 
DM), and HIGH (feedlot consultant recommendations of 20 mg Cu/kg DM; Samuelson et al. (2016)). Supplementation of Cu 
was delivered as Availa Cu (Zinpro Corporation, Eden Prairie, MN) and all other minerals were supplemented at national 
recommendations utilizing inorganic sources 
4Initial weights from prior trial were used as covariate for carcass data analysis. 
5Hot carcass weight 
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6Marbling scores: slight=300, small=400, modest=500, moderate=600, slightly abundant=700, moderately abundant=800. 
7Kidney pelvic heart fat 
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Figure 1. The effect of ractopamine hydrochloride (RAC) on serum NEFA 
concentrations during BA period. A tendency for a BA × Day interaction 
was observed (P = 0.08). Cattle were supplemented with 0, 10, or 20 mg 
Cu/kg DM for LOW, MED, and HIGH dietary Cu treatments and either 0 or 
300 mg·steer-1·day-1 of ractopamine hydrochloride (RAC) for 28 days prior 
to harvest.  
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CHAPTER 4. EFFECT OF TWO DIETARY COPPER TREATMENTS ON 
IMPLANT PERFORMANCE RESPONSE AND CARCASS CHARACTERISTICS 
OF FINISHING BEEF STEERS 
A paper to be submitted to the Professional Animal Scientist 
E.M. Messersmith, D.D. Loy, and S.L. Hansen 
Department of Animal Science, Iowa State University, Ames, IA 50011 USA 
Abstract 
Sixty Angus-cross steers (477 ± 32 kg) were assigned equally to a 2 × 2 factorial 
to determine the effect of dietary Cu on implant elicited growth. Factors included Cu 
supplementation at 0 (CON) or 20 mg Cu/kg DM (IND) from CuSO4 and implant (IMP) 
administered on d 0 as no implant (NoIMP) or Component TE-200 (TE-200; 20 mg 
estradiol + 200 mg TBA; Elanco Animal Health, Greenfield, IN). Steers were blocked to 
dietary treatments by initial liver Cu concentrations; 97 and 188 mg Cu/kg DM (P = 
0.001) for CON and IND treatments, respectively, and stratified by BW to pens (6 
steers/pen) for a 74 d study. Liver and blood samples were taken prior to start of trial, 14 
days after implant, and before harvest. Steer was the experimental unit (n = 15 per 
treatment) and initial BW and liver Cu concentrations were used as covariates in analysis 
of performance and liver Cu concentrations, respectively. TE-200 increased BW, HCW, 
and ribeye area (P ≤ 0.01). There tended to be an IMP × Cu interaction (P = 0.13) in 
which CON elicited a greater live ADG response to implant than IND. Liver Zn 
concentrations tended to decrease (P = 0.07) while liver Mn was lesser (P = 0.001) on d 
14 due to implant. Plasma Cu and ceruloplasmin concentrations were greater due to IND 
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treatment within TE-200, but lesser due to IND within NoIMP (IMP × Cu; P ≤ 0.13). 
These results suggest dietary Cu concentrations may impact growth response in 
implanted steers and implants may alter trace mineral metabolism. 
Key words: beef cattle, copper, implant, trace minerals  
Introduction 
Implants are commonly used in the beef industry; 70% of cattle represented in a 
survey of consulting nutritionists are implanted with a two implant protocol (Samuelson 
et al., 2016). Furthermore, use of combination implants allows for greater feed efficiency 
and increased growth rate in comparison to single hormone implants and nonimplanted 
cattle (Bartle et al., 1992). Additionally, the use of  two combination implants can result 
in a 7.5 and 9% increase in HCW and ribeye area (REA), respectively, in comparison to 
nonimplanted cattle (Duckett and Pratt, 2014). This increased growth suggests cattle may 
have a greater requirement for trace minerals such as copper. The role of Cu in growth is 
exerted in part through the Cu dependent enzyme lysyl oxidase, which is responsible for 
crosslinking of collagen and elastin in the extracellular matrix (Rucker et al., 1998). 
Lambs implanted with 12 mg zeranol, a synthetic estrogen derivative, tended to have 
lesser fecal excretion and greater absorption of Cu than nonimplanted lambs (Hufstedler 
and Greene, 1995). Further, steers initially implanted with a combination implant 
containing 16 mg estradiol (E2) and 80 mg trenbolone acetate (TBA) and re-implanted 
with a combination implant containing 20 mg E2  and 200 mg TBA had decreased liver 
Cu concentrations 14 days after reimplantation relative to non-implanted steers 
(Niedermayer et al., 2018). These data suggest that hormone implants may impact Cu 
metabolism of ruminants. Little work has been done to determine mineral requirements 
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of cattle utilizing growth promoting technologies such as implants. Therefore, the 
objective of this study was to determine the effects of Cu supplementation on 
performance of steers receiving a potent hormone implant or no implant. It was 
hypothesized that steers supplemented with Cu would exhibit a greater growth response 
to implantation compared to steers not supplemented with Cu and Cu supplementation 
would have little effect on growth of nonimplanted steers.  
Materials and Methods 
All procedures and protocols in this study were approved by the Iowa State 
University Institutional Animal Care and Use Committee (log number 2-18-8701-B). 
Animals and experimental design 
Sixty Angus-cross steers (477 ± 32 kg) were housed in partially-covered pens 
with concrete bunks and automatic waterers.  Steers utilized in the present trial were 
previously enrolled in another trial, in which the Cu antagonists S and Mo were fed to 
develop distinct Cu statuses. At the start of the present study steers were blocked by 
initial liver Cu status and stratified to pens (6 steers per pen; n = 10 pens total) by BW.  
Pens were randomly assigned to dietary treatments. Cattle were fed a common dry rolled 
corn based TMR supplemented with NASEM (2016) recommendations of all minerals 
except for Cu (Table 1). The diet was delivered at approximately 0800 h daily and bunks 
were managed to be slick at feed calls approximately 30 minutes prior to feed delivery.  
Experimental treatments were arranged as a 2 x 2 factorial, with 2 dietary Cu 
treatments: 1) control (CON) common TMR with no supplemental Cu, and 2) industry 
Cu supplementation (IND) common TMR supplemented with 20 mg Cu/kg DM from 
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CuSO4. To complete the factorial two implant strategies (IMP) were utilized: 1) no 
implantation (NoIMP) or implanted with a Component TE-200 (TE-200; 20 mg E2 + 200 
mg TBA; Elanco Animal Health, Greenfield, IN). Implant treatments were distributed 
equally among pens (3 steers per treatment per pen).The industry treatment was chosen to 
be representative of industry consultant recommendations for Cu (Samuelson et al., 2016) 
in contrast to NASEM (2016) recommendations of 10 mg Cu/kg DM. The common diet 
analyzed to contain 4.5 mg Cu/kg DM and the IND diet analyzed to contain 21.6 mg 
Cu/kg DM. The implant utilized was Component TE-200 (20 mg E2 + 200 mg TBA) 
given on day 0 of the present trial. All steers were previously implanted with a 
Component TE-IS (16 mg E2 + 80 mg TBA; Elanco Animal Health, Greenfield, IN) 107 
days prior to the initiation of the present trial.  
Sample collection and analysis 
Body weight was recorded on consecutive days to start (d -1, 0) and end (d 73 and 
74) the trial, and interim weights were recorded on d 13, 28, and 55. For calculations of 
BW and ADG a 4% pencil shrink was applied to all live BW. Liver biopsies were 
conducted on d -23, 14, and 62 on 4 steers per pen (2 implanted and 2 nonimplanted) 
following the method described by Engle and Spears (2000) and blood samples were 
collected on d 0, 14, and 73 from the same steers (n = 40 total, 10 per treatment). Cattle 
were shipped to a commercial abattoir (Iowa Premium Beef, Tama, IA) on d 74, 
harvested on d 75 and HCW were recorded. Carcasses were chilled for 48-hours and 
carcass data were collected including REA, back fat (BF), KPH, marbling score, and YG. 
Dressing percent was calculated as HCW divided by shrunk final BW and multiplied by 
100. 
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For each dietary treatment TMR were sampled weekly and dried in a forced air 
oven at 70˚C for 48-hour to calculate DM content of the diet. Dry matter content of 
weekly TMR were applied to as fed feed disappearance for each pen to determine pen 
DMI. Dried diet samples were ground through a 2-mm screen (Retsch Zm100 grinder; 
Glen Mills Inc., Clifton, NJ) and samples were composited by month. Composited TMR 
samples and liver samples were acid digested with trace mineral grade nitric acid (Fisher 
Scientific, Fair Lawn, NJ) as previously described by Richter et al. (2012). Plasma, liver, 
and TMR samples were analyzed for mineral content utilizing inductively coupled 
plasma optical emission spectrometry (ICP Optima 7000 DV, Perkin Elmer, Waltham, 
MA). Blood samples were collected in vacutainer tubes with no additives for serum and 
trace mineral grade EDTA for plasma collection (Becton Dickenson, Rutherford, NJ). 
Blood was centrifuged at 1200 × g for 10 mins for plasma and 1200 × g for 20 mins for 
serum samples.  Plasma samples were analyzed for ceruloplasmin concentration 
described by Demetriou et al. (1974).  
Statistical analysis 
Data were analyzed as a 2 × 2 factorial using the Mixed procedure of SAS 9.4 
(SAS Inst. Inc., Cary, NC) with the fixed effects of Cu, Implant, and Cu × Implant. The 
experimental unit was steer (n = 15 per treatment for growth and carcass data; n = 10 per 
treatment for liver and blood data). Initial liver Cu (day -109) and BW (day -107) from 
the previous trial were used as covariates in liver Cu and performance analysis, 
respectively. Blood parameters were analyzed as repeated measures, and the compound 
symmetry covariant structure was selected based on the lowest corrected Akaike’s 
information criterion. In addition, plasma Cu, Zn, and ceruloplasmin data were log 
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transformed to normalize the data, and back transformed means and standard errors are 
reported. Cook’s D was used to evaluate data for outliers, and two data points for the 
IND-TE-200 treatment were removed from plasma Cu and Zn analysis. Data reported are 
least square means with standard error of the means. Statistical significance was 
determined at P ≤ 0.05, with tendencies defined as 0.05 < P ≤ 0.13. 
Results and Discussion 
The wide use of combination implants in the feedlot industry presents an 
opportunity to improve cattle performance through innovative strategies such as Cu 
supplementation which may support implant induced growth. While feedlot consultants 
report supplementing Cu at two times (Samuelson et al., 2016) the NASEM (2016) 
recommendation, the effect of this range of Cu supplementation on performance of 
implanted cattle has not previously been examined. In the present 74-d finishing trial, live 
final BW of TE-200 steers was greater than NoIMP steers by an average of 24 kg (P ≤ 
0.001; Table 2). Because TE-200 and NoIMP steers were housed in pens together, 
individual animal DMI data are not available in the present trial. However, overall DMI 
between CON (11.6 kg/d) and IND (11.8 kg/d) did not differ (P = 0.51). A tendency for 
an IMP × Cu interaction was detected for overall live ADG (P = 0.13). Unexpectedly, 
CON steers displayed a 24.7% increase in overall ADG when implanted, while IND 
supplemented steers had a 15.3% ADG increase due to implant. This improvement due to 
implant for IND steers is in agreement to Smith et al. (2007) where steers implanted with 
a combination implant (28 mg estradiol benzoate + 200 mg TBA), had a 16% increase in 
ADG compared to non-implanted controls. These data contrast the 33% increase in ADG 
due to implant observed in steers with a similar terminal implant program to present trial 
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(20 mg E2 + 200 mg TBA; Niedermayer et al., 2018). However, without an intermediate 
Cu treatment it is unclear if CON steers had better than expected performance or if IND 
steers underperformed in response to implant. Although an implant response was 
observed in both CON and IND steers, the degree of response implies that growth elicited 
by this combination implant was influenced by Cu status of the steer. 
There were no IMP × Cu interactions for HCW, REA, BF, KPH, YG, or DP (P ≥ 
0.21; Table 2). Additionally, carcass characteristics were unaffected by Cu treatment (P 
≥ 0.16) and KPH, YG, and DP were unaffected by implant treatment (P ≥ 0.30). Previous 
work has suggested that Cu supplementation can increase leanness of the carcass through 
decreased BF thickness (Engle et al., 2000; Engle and Spears, 2000; Johnson and Engle, 
2003); however, this response to Cu supplementation was not observed in this study. 
Rather, BF tended to increase due to implant treatment (P = 0.12). Implant also increased 
HCW and REA of steers (P ≤ 0.01). Additionally, a tendency for an IMP × Cu interaction 
(P = 0.12) was observed influenced by the lesser marbling score of CON-TE-200 steers 
while IND-TE-200 marbling remained no different than NoIMP steers. A decrease in 
marbling score due to implants has been observed by others (Bartle et al., 1992), 
however, controlling days on terminal implant (74 d in present study) has been suggested 
as a way to manage impact of implants on carcass quality.   
Considering the rapid growth that ensues in response to implantation, dietary 
mineral inclusions may be of great importance to accommodate this growth. In the 
current study, no IMP × Cu interactions were observed for liver mineral concentrations. 
Although liver Cu concentrations of steers in CON and IND treatments measured on d 14 
or 62 remained quite distinct (P = 0.001; Table 3) both treatments maintained adequate 
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liver Cu status (Kincaid, 2000). Reference ranges for liver Cu as suggested by Kincaid 
(2000) are: deficient (< 33 mg Cu/ kg DM), marginal (33 to 125 mg Cu/kg DM), and 
adequate (125 to 600 mg Cu/kg DM). The combined average liver Cu status of 97 mg 
Cu/kg DM prior to the start of the trial for CON steers is beyond the state of deficiency 
and would be recognized as physiologically normal although in the top range of the 
marginal status. Additionally, during deficiency plasma Cu would be expected to fall 
below 0.50 μg/mL (Kincaid, 2000). Subsequently, all steers in this study would be 
considered adequate based on plasma Cu concentrations as values did not fall below 0.87 
μg/mL. Further, steers fed the IND treatment had on average 91 and 250 mg/kg DM 
greater liver Cu concentrations than CON steers at the beginning and end of the trial, 
respectively. That steers with these differences in liver Cu had differential ADG in 
response to a combination implant suggests the adequate liver Cu status range requires 
further classification to define a more optimal liver Cu status for growth.  
Interestingly, mineral status of the steers measured through liver and plasma 
concentrations (Table 3) suggest that implant may affect mineral metabolism in cattle. 
However, 14 days after implantation, when hormone payout from implant would be 
expected to be greatest, liver Cu concentrations tended to be greater in implanted cattle 
(P = 0.13). In contrast, liver Cu was decreased 14 days after implantation (20 mg E2 + 
200 mg TBA) in a previous trial supplementing various trace mineral concentrations to 
steers (Niedermayer et al., 2018). These differences may be due to the timing of implant 
between studies. Niedermayer et al. (2018) measured Cu status after steers had been on 
dietary mineral treatments for 70 days while the present trial collected liver samples after 
only 14 days of Cu supplementation. However, steers were assigned to dietary Cu 
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treatments in the present trial based on previous Cu nutrition, thus liver Cu concentrations 
were already distinct at the start of the trial. This blocking of cattle by liver Cu into 
dietary treatments led to consistently greater liver Cu in IND steers than CON steers 
through the entirety of the trial (P = 0.001).  The present trial contrasts work in rats in 
which estrogenic treatment has been shown to decrease liver Cu concentrations, 
suggesting the use of hormonal implants may elicit a similar response (Evans et al., 
1970). Additional work observed an increase in Cu retention in sheep implanted with 12 
mg zeranol further implying that hormonal implants affect Cu metabolism (Hufstedler 
and Greene, 1995).  
In addition to the change in liver Cu status, a decrease in liver Mn on d 14 after 
implant (P = 0.001) is consistent with previous implant work in steers suggesting Mn 
metabolism is influenced by combination implants (Niedermayer et al., 2018). Liver Mn 
tended to remain lesser (P = 0.08) in implanted steers and was lesser in CON steers 
compared to IND steers (P = 0.002) near the end of the present trial (d 62). Additionally, 
an observed tendency for lesser fecal excretion and greater absorption of Mn in lambs 
implanted with 12 mg zeranol is congruent with these data (Hufstedler and Greene, 
1995). Liver Mn is generally tightly controlled as Mn homeostasis in the liver is well 
maintained with minimal changes beyond the constant influx of Mn from the plasma and 
removal to the bile (Kincaid, 2000). It is unclear why Cu treatment impacted liver Mn; 
however, decreased liver Mn due to implant suggests the implant response may require 
more Mn to account for added growth or there is less need for Mn in the liver during 
times of rapid growth. The later of these hypotheses may be due to the role of Mn in the 
urea cycle through Mn dependent arginase (Watts, 1990). During more rapid growth 
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circulating amino acids may be utilized by muscle cells, resulting in less ammonia 
needing to be detoxified in the urea cycle. However, the role of Mn in growth is largely 
thought to be in support of glycosyltransferase and proteoglycan roles in skeletal 
development (Leach, 1986). Use of estrogenic implants in beef cattle has been 
demonstrated to increase skeletal growth in late stage finishing cattle (Loy et al., 1988). 
Manganese is physiologically important in carbohydrate metabolism, contributing to the 
production of energy to support rapid growth (Scrutton et al., 1966; Failla, 1986; Watts, 
1990) and thyroid function is dependent upon Mn for the production of thyroxine 
(Pfeiffer, 1975). It is important to note that alterations in liver Mn concentration alone 
due to implant do not indicate if or how Mn is being used or if it is being excreted. 
Therefore, more work to understand the physiological relevance of this decreased liver 
Mn due to implant is needed.  
Liver Zn also tended to be lessened by implant on day 14 (P = 0.07) but was 
unaffected by implant on d 62 (P = 0.69) suggesting a greater demand for Zn at the time 
of expected maximum hormone payout. However, liver Zn was not affected by Cu 
treatment (P ≥ 0.16).  Implant has been shown by others to affect liver Zn concentrations. 
Fed no supplemental Zn, and 59 days after receiving a combination implant (20 mg 
estradiol benzoate + 200 mg progesterone), implanted steers had lesser liver Zn 
concentrations than nonimplanted steers  (Huerta et al., 2002). In the same study steers 
fed no supplemental Zn (basal diet contained 84 mg Zn/kg DM) or supplemented with 
200 mg Zn/kg DM from Zn sulfate experienced a 7.6 and 17.4% increase in weight gain, 
respectively, due to implant (Huerta et al., 2002). Using a different growth promoting 
technology, Genther-Schroeder et al. (2016) reported decreased liver Zn concentrations in 
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steers after 26 d of ractopamine hydrochloride supplementation, even when steers were 
supplemented with dietary Zn. Plasma Zn concentrations (Figure 1) across the present 
trial were lesser on d 13 and 73 due to implant (IMP × Day; P = 0.001). No IMP × Cu × 
Day (P = 0.22) or IMP × Cu (P = 0.42) interactions were observed in the plasma data, but 
Cu tended to decrease plasma Zn (P = 0.13). These changes in tissue Zn concentrations 
may indicate a demand for Zn in support of increased skeletal and muscle growth of 
implanted steers. Dietary Zn has been shown to increase N retention suggesting Zn has an 
important role in accommodating rapid muscle growth (Carmichael et al., 2018) and 
more work is needed to refine dietary Zn requirements of cattle receiving hormone 
implants.  
While increasing supplemental Zn may support improved growth response to 
growth promoting technologies (Huerta et al., 2002; Genther-Schroeder et al., 2016), data 
from the present trial suggest Cu concentrations commonly supplemented in the industry 
negatively impact implant response. The differential growth response observed in CON 
and IND steers to implant treatment indicates a physiological difference due to low 
dietary Cu supplementation. However, the reasoning behind this response remains 
unclear. The importance of Cu in supporting growth is through collagen crosslinking via 
lysyl oxidase (Rucker et al., 1998). It is likely that the activity of this enzyme alone does 
not explain the differences in growth response exhibited by IND steers. Cattle 
supplemented with 10 or 20 mg Cu/kg DM from Availa Cu (Cu- amino acid complex) 
had greater HCW than un-supplemented controls suggesting Cu positively impacts 
growth (Johnson and Engle, 2003). In contrast, increasing dietary Cu concentration up to 
40 mg Cu/kg DM has previously not yielded improved performance (Ward et al., 1993; 
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Engle and Spears, 2000; Engle and Spears, 2001). Cattle response to Cu supplementation 
is likely a function of rate of growth, cattle genetics, and presence of basal amounts of Cu 
or Cu antagonists in the diet.  
There tended (P = 0.13) to be an interaction between IMP and Cu for plasma Cu 
concentrations and was an interaction (P = 0.05) for plasma ceruloplasmin 
concentrations. For both variables, concentrations were greater in IND within TE-200, 
but lesser in IND within NoIMP. Previous work in rats has shown an increase in 
circulating ceruloplasmin concentrations due to estrogen treatment (Sunderman et al., 
1971). These data suggest the estrogen dose from the Component TE-200 implant (20 mg 
E2 + 200 mg TBA) may have resulted in the spike of plasma ceruloplasmin in IND 
supplemented steers. The increase in plasma Cu in accordance with ceruloplasmin was 
expected as ceruloplasmin functions as a carrier protein for Cu (Percival and Harris, 
1990). 
Due to the potency of the implant utilized in this study (20 mg E2 + 200 mg 
TBA), physiological effects of these hormones on trace minerals may be expected, 
though this is poorly understood in cattle. In human liver cancer cells incubated with 
different concentrations of Cu in the media, absorption of Cu in cells incubated with E2 
was increased and remained greater following the removal of E2 (Arredondo et al., 2010). 
While Cu transport proteins DMT1 and CTR1 are typically increased or decreased in 
response to cellular Cu availability, incubation with 17-β E2 ablated this regulatory effect 
of Cu in human liver cancer cells (Arredondo et al., 2010). These findings suggest that in 
the presence of estrogen, cellular Cu machinery may be altered to maintain increased 
cellular Cu concentrations, perhaps to support increased growth. However, further work 
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is needed to understand the mechanisms by which estrogen may affect the Cu 
requirement in ruminants.  
Implications 
Overall, these results indicate that growth performance is differentially affected 
by dietary Cu concentrations in response to administration of a hormonal implant. It also 
appears there is a relationship between implants and the trace minerals Zn and Mn, as 
lesser liver Zn and Mn concentrations were observed after implantation. Further, the IMP 
× Cu interactions observed in both plasma Cu and ceruloplasmin concentrations indicate 
Cu metabolism is affected by hormone implants, potentially in relation to the known 
effects of estrogen on components of Cu biology. The extent to which Cu, Zn, and Mn 
are involved in the biological implant response remains largely unknown; however, these 
data suggest minerals may have a role in the growth response elicited from hormonal 
implant technology. It appears the industry average supplementation of nearly two times 
NASEM (2016) recommendations for Cu may hinder the implant growth response. 
Through better understanding the trace mineral requirements of hormone implanted 
cattle, the cattle feeding industry can move toward more strategic supplementation of 
trace minerals to improve efficiency and performance of cattle and thus profitability for 
cattle producers. 
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Table 1. Ingredient and composition analysis of control diet  
Ingredient % of diet DM 
     Dry rolled corn                             62.0 
     MDGS1                             25.0 
     Bromegrass hay                               8.0 
     DDGS2                                 3.05 
     Limestone                               1.5 
     Salt                                 0.31 
     Vitamin & mineral premix3                                 0.13 
     Rumensin                                     0.0135 
Analyzed composition  
     CP4                              15.3 
     NDF4                              18.0 
     Ether extract4                               5.8 
     Sulfur4                                0.28 
     Copper, mg/kg DM5                                4.5 
     Zinc, mg/kg DM6                             61  
1Modified distillers grains with solubles. 
2Dried distillers grains with solubles. 
3Premix provided 2,200 IU vitamin A and 25 IU vitamin E/kg diet 
DM and NASEM (2016) recommendations for Co, Mn, Se, Zn, and I 
from inorganic sources. CON premix contained no additional Cu, 
while IND premix provided 20 mg Cu/kg diet DM from Cu sulfate. 
4Analysis of CON TMR by Dairyland Laboratories (Arcadia, WI). 
5Analyzed Cu represents CON dietary treatment total with no 
supplemental Cu. IND dietary treatment was analyzed to contain 21.6 
mg Cu/kg DM by inductively coupled plasma optical emission 
spectrometry (ICP Optima 7000 DV, Perkin Elmer, Waltham, MA). 
6Analyzed Zn represents CON dietary treatment with NASEM (2016) 
recommendations for Zn supplemented. IND treatment analyzed to 
contain 58 mg Zn/kg DM by inductively coupled plasma optical 
emission spectrometry (ICP Optima 7000 DV, Perkin Elmer, 
Waltham, MA). 
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Table 2. Effect of implant strategy1 and copper supplementation2 on growth and carcass characteristics 
 NoIMP TE-200  P-value 
 CON IND CON IND SEM IMP3 Cu IMP × Cu 
steers (n)   15   15   15   15     
Live performance4 5         
   d 0 BW, kg 475 480 479 475   5.6 -    0.90 - 
   d 73 BW, kg 595 605 628 620   7.1 0.001    0.91 0.19 
   Overall ADG, kg     1.62     1.70     2.02     1.96   0.045    0.001    0.87      0.13 
CA performance4 5 6         
   d 74 BW, kg 596 608 627 618   7.9    0.01    0.87      0.21 
   Overall ADG, kg     1.62     1.69     1.98     1.91   0.052    0.001    0.94      0.18 
Carcass characteristics4 5          
   HCW, kg 383 390 402 397   5.0    0.01    0.87      0.21 
   Ribeye area, cm2   84.3   86.0   89.7   89.9   1.56    0.004    0.56      0.63 
   Back fat, cm     1.72     1.75     1.94     1.88   0.112    0.12    0.86      0.69 
   KPH     2.4     2.5     2.5     2.6   0.06    0.30    0.16      0.62 
   Marbling7 534 511 459 510 23.6    0.11    0.55      0.12 
   YG     3.71     3.72     3.83     3.73   0.144    0.67    0.77      0.70 
   DP, %   64.3   64.4   64.0   64.0   0.32    0.30    0.88      0.95 
1Implant treatment (IMP) consisted of either a Component TE-200 implant (TE-200; 20 mg estradiol + 200 mg TBA; Elanco 
Animal Health, Greenfield, IN) on day 0 of the trial or no hormone implant (NoIMP). 
2The CON treatment received no supplemental Cu whereas the IND treatment received 20 mg Cu/kg DM from CuSO4 per 
feedlot consultant recommendations (Samuelson et al., 2016). 
3IMP represents all steers in the TE-200 treatment for implant regardless of Cu treatment. 
4A 4% pencil shrink was applied to all live BW prior to analysis. 
5Beginning weight from prior trial was used as covariate in analysis. 
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6Carcass adjusted (CA) overall performance was determined with the average DP of the group (64.20%). 
7Marbling scores: slight=300, small=400, modest=500, moderate=600, slightly abundant=700, moderately abundant=800. 
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Table 3. Effect of implant strategy1 and copper supplementation2 on liver and plasma mineral parameters 
 NoIMP TE-200  P-value 
 CON IND CON IND SEM IMP3 Cu IMP × Cu 
steer (n)   15   15   15   15     
Liver Cu, mg/kg DM4         
   d -23 (initial)   92 197   101 178   3.6 -   0.001 - 
   d 14 117 202 138 207   4.0      0.13   0.001     0.27 
   d 62   95 344   89 339   4.4      0.62   0.001     0.75 
Liver Zn, mg/kg DM         
   d 14 126 131 119 121     2.0      0.07   0.37     0.77 
   d 62 114 117 111 117     1.5      0.69   0.16     0.76 
Liver Mn, mg/kg DM         
   d 14     9.6     9.7     8.2     8.6     0.13      0.001   0.43     0.55 
   d 62     8.9     9.7     8.1     9.5     0.13      0.08   0.002     0.30 
Plasma5         
   Cu, mg/L     0.93     0.89     0.87     0.93     0.015      0.72   0.71     0.13 
   Ceruloplasmin, mg/dL   23.8   21.6   22.3   24.3     0.62      0.91   0.63     0.05 
1Cattle within the implant treatment received Component TE-200 (TE-200; 20 mg estradiol + 200 mg TBA; Elanco Animal 
Health, Greenfield, IN) on day 0 of the trial. Non-implanted (NoIMP) cattle did not receive an implant. 
2Cu supplementation treatments included CON with no supplemental Cu and IND providing 20 mg/kg DM of supplemental Cu 
from Cu sulfate in the diet as recommended by industry consultants per Samuelson et al. (2016). 
3IMP represents all steers in the TE-200 implant treatment regardless of Cu supplementation treatment. 
3Liver Cu from the beginning trial (d -23) was used as covariate in analysis. 
4Data analyzed as repeated measures, no interactions with day (P ≤ 0.15).   
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Figure 1. Effect of implant (TE-200) or no implant (NoIMP) and day on 
plasma Zn concentrations (IMP × Day P = 0.001; SEM = 0.075). Cattle 
receiving the TE-200 treatment were implanted with Component TE-200 (20 
mg estradiol + 200 mg TBA; Elanco Animal Health, Greenfield, IN) on day 
0 of trial. Unlike superscripts indicate means differ (P ≤ 0.05). 
  
124 
 
 
CHAPTER 5. GENERAL CONCLUSIONS 
Growth promoting technologies such as beta agonists and steroid hormone 
implants are extensively used within the feedlot industry. The increased growth rates 
observed through the use of these technologies may suggest a greater demand for 
nutrients such as Cu, which supports development of extracellular matrix through 
collagen remodeling via lysyl oxidase (Rucker et al., 1998). There is evidence from the 
basic literature that Cu may impact the biological pathways downstream of both beta 
agonists and steroid hormones. Additionally, feedlot nutritionists often report 
supplementing Cu well in excess of the national recommendations for Cu (Samuelson et 
al., 2016). Therefore, these research studies were designed to gain an understanding of 
the impact of supplemental Cu concentrations and animal Cu status on growth and 
carcass characteristics of steers receiving growth promoting technologies. 
 This research stemmed from the limited data available on effects of trace mineral 
supplementation on performance of cattle receiving either a beta agonist or hormone 
implant. It was hypothesized that cattle growth would linearly increase as Cu 
supplementation increased in diets of cattle receiving the beta agonist ractopamine 
hydrochloride. This hypothesis is partially based upon the recent revelation that both Zn 
and Cu reversibly inhibit the enzymatic activity of phosphodiesterase (PDE) and thus 
influence the availability of cyclic AMP (cAMP) to subsequently stimulate lipolysis 
downstream of beta adrenergic receptor activation (von Bulow et al., 2005; 
Krishnamoorthy et al., 2016). Increases in plasma cAMP in steers supplemented with 
increasing concentrations of Zn, and increasing growth of steers receiving both Zn and 
ractopamine hydrochloride support these findings (Genther-Schroeder et al., 2016). 
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Supplementation of Cu was also found to differentially affect performance of steers 
receiving or not receiving a beta agonist. However, in contrast to the linear improvements 
noted during increasing Zn supplementation, steers utilized in the present research 
exhibited maximal growth at NASEM (2016) rates of supplementation (10 mg Cu/kg 
DM) during the beta agonist feeding period. In addition, the NASEM (2016) rate of Cu 
supplementation tended to improve ribeye area of steers utilizing beta agonists, but 
further carcass characteristics were unaffected due to the varying Cu supplementation 
treatments. This is in opposition to our hypothesis of continually improved growth due to 
increasing Cu supplementation during the beta agonist feeding period. These 
performance differences may have been driven by the liver Cu concentrations of steers. 
Although liver Cu concentrations of steers in treatments supplemented with Cu were 
within the adequate range, differential growth responses suggest that more work is 
needed to refine liver Cu concentrations that may best support cattle growth. It is unclear 
why feedlot consultants often supplement 20 mg Cu/kg DM; however, data from this 
work suggest this rate of Cu supplemented in the industry is not optimal for beta agonist 
induced growth. Furthermore, it appears that Cu and Zn have differential impacts on beta 
agonist induced growth performance in cattle.  
 In addition to the beta agonist pathway, tissue Cu appears to be affected by 
hormone implants. Sheep implanted with 12 mg zeranol, an estrogen derivative, tended to 
have greater Cu retention than nonimplanted sheep (Hufstedler and Greene, 1995). 
Through the use of a combination implant in steers a decrease in liver Cu status of 
implanted steers during the period of greatest hormone payout was observed 
(Niedermayer et al., 2018). Therefore, Cu was targeted to further determine its potential 
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role in implant growth response. Through this implant study, Cu treatment again resulted 
in a differential performance due to growth promoting technology. The greater degree of 
increase in growth for cattle receiving no supplemental Cu in comparison to cattle 
supplemented with an industry average suggests the industry may be supplementing more 
Cu than needed, potentially depressing implanted cattle performance. Alternatively, non-
Cu supplemented steers may have responded better than expected to the combination 
implant, potentially because of the relationship between estrogen and bodily Cu 
metabolism. Further, implant treatment tended to increase liver Cu, decrease Mn and 
tended to decrease Zn during the period of greatest hormone payout. These findings 
suggest hormone implants are affecting tissue mineral concentrations and more work is 
needed to refine the potential implications on cattle performance these changes may be 
having. Additionally, future work should be undertaken utilizing multiple concentrations 
of dietary Cu fed to cattle receiving hormone implants to better understand the 
relationship between these two management factors.  
 Through both of these studies it is clear Cu supplementation and status are 
impactful on the performance of steers utilizing growth promoting technologies. 
Additionally, industry average supplementation of Cu may be adversely affecting 
performance of cattle utilizing these two technologies. To better understand the role of 
Cu in these growth responses the initial Cu status of the animal must be taken into 
consideration as well as dietary constraints such as antagonists. Additional work is 
warranted to further refine the optimal liver Cu status as well as rate of Cu 
supplementation to support growth induced by these promotants.  
 
